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ABSTRACT 
Hibiscus sabdariffa (HS) is a plant of the Malvaceae family that has anti-obesity, 
antihypertensive, hypocholesterolaemic, anti-oxidant and anti-cancer properties. Dietary 
manipulations during the suckling period cause precocious maturation of the gastrointestinal 
tract (GIT). Events in early life affect the individual‘s metabolic health in later life. This study 
investigated the effects of early administration of the aqueous calyx extracts of HS on the 
growth performance, general health and the GIT of neonatal rats and whether it conferred 
protection or predisposition to the development of metabolic dysfunction in adolescence. 
The study was carried out in two phases. The first phase was to determine the effects of HS 
aqueous calyx extracts on the growth performance, metabolic substrates and the development 
of the neonatal rat GIT. In the second phase, the effects of the early administration of the HSE 
on the response of the pups to diet induced metabolic dysfunction were investigated. 
In phase one, forty two 4-day old Sprague Dawley pups of both sexes were randomly 
assigned to three treatment groups. Each group consisted of 7 males and 7 females. The 
control group received distilled water at 10ml.kg
-1
 b.w while the other two groups received 
either a low (50mg.kg
-1
) or high dose (500mg.kg
-1
) of the HS aqueous calyx extracts via oral 
gavage daily for 9 consecutive days. The rats were euthanased and their tissues harvested and 
analyzed.  Pups that were administered with the high dose HSE had significantly heavier 
small intestines relative to the body mass when compared to those on the low dose HSE 
(P<0.01) and the control group (p<0.001). Pups in the high dose HSE group had significantly 
heavier caeca (p<0.05) than those in the low dose HSE group. 
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In the second phase, eighty five 4-day old Sprague Dawley rat pups were used. They were 
initially divided randomly into three groups and received similar treatments as in phase one 
up to postnatal day (PND) 14. There was no intervention from PND14 to PND 21 when the 
pups were weaned. The rats in each of the treatment groups were further divided into a control 
group that continued on their normal rat chow diet and a test group that received high fructose 
(20% w/v) in their drinking water for 30 days in order to induce metabolic dysfunction. Each 
of the six study groups had at least 5 male and 5 female rats. The male rats in each of the 
treatment groups gained more body mass than their corresponding female counterparts in the 
control and treatment groups (p<0.001). Female rats that received high dose HSE in the 
neonatal period had significantly greater visceral fat pad (p≤0.05) than the males in the 
groups. There were no negative effects on the rats‘ general health. At the end of the study, 
features of metabolic syndrome did not manifest in the control or any of the treatment groups.  
Hibiscus sabdariffa aqueous calyx extracts did not exhibit any long term effects and therefore 
may be considered safe for consumption in the neonatal age group. 
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1.0 Preface 
Modernization has brought with it several issues amongst which are those that affect the 
health of mankind. Sedentary lifestyles combined with an increase in the consumption of 
energy-packed foods result in under-expenditure of daily caloric intake. 
 
Consequently, the incidence of metabolic dysfunction such as obesity, dyslipidaemia and 
hyperglycaemia are on the increase worldwide. The aggregation of these metabolic problems 
in an individual is called metabolic syndrome, a condition which predisposes to the 
development of cardiovascular disease and type 2 diabetes mellitus.  The incidence of 
childhood obesity and its associated medical and social complications is on the increase. 
 
Events in the foetal and early neonatal environment have been linked to the development of 
metabolic syndrome in the adolescent and adult life. In the current management of metabolic 
syndrome, its risk factors are targeted with drugs such as fenofibrate, antihypertensives and 
hypoglycaemic agents. However, in many communities, medicinal plants are used because of 
their affordability and availability as opposed to the conventional drugs. While some of these 
plants have been fully characterized and their uses documented, there are many others whose 
potential beneficial or harmful effects have not been explored. 
 
Hibiscus sabdariffa (HS) is one of such plants that have been exploited by researchers due its 
many scientifically proven activities which include antihypertensive, antidiabetic, 
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hypocholesterolaemic and anticancer among others. Extracts from its calyces contain a battery 
of phytochemicals including anthocyanins. The latter have antioxidant properties and protect 
the body against peroxidative damage. A detailed discussion on HS will follow in this chapter 
regarding its (HS) many uses and potential. 
 
Hibiscus sabdariffa extracts are usually prepared into decoctions which are ingested orally 
thus coming into contact directly with the gastrointestinal tract (GIT). Research has shown 
that some plant extracts when administered during the suckling period can cause precocious 
maturation of the GIT (Linderoth et al., 2005).  
 
This study therefore looked at the effects of HS calyx extracts on the growth performance, 
clinical biochemistry, and neonatal GIT morphometry; and also investigated whether its 
consumption in early life conferred some form of protection or predisposition to the 
development of metabolic dysfunction in the growing period.  
 
1.1 Structure of the dissertation 
 
This dissertation was written in five chapters. In the first chapter a general introduction was 
provided which included a discussion on the definitions and prevalence of metabolic 
syndrome. The botanical classification, traditional uses, phytochemistry, pharmacology and 
toxicology of Hibiscus sabdariffa plant were provided. The chapter also covered the 
justification, aims and objectives and the hypotheses of the study. 
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In the second chapter, the first phase of the study was reported.  It covered discussions on the 
GIT, phytochemicals and their effects on health and the effects of HS on the GIT. The first 
experiment was described under the headings: materials and methods, results, discussion and 
conclusion. 
 
The second phase of the study was presented in the third chapter.  An introductory discourse 
was given on neonatal programming, childhood obesity and fructose-induced metabolic 
dysfunction. The materials and methods, results, discussion and conclusions of the second 
experiment were also presented in this chapter. 
 
The fourth chapter covered the conclusions and recommendations that arose from the study 
while in the fifth chapter a list of all the references cited in the study was provided. Some 
appendices are also included. 
 
1.2 Introduction 
 
Metabolic syndrome, a condition which predisposes those affected to the development of type 
2 diabetes mellitus and cardiovascular disease (Ford and Li, 2008), is a collection of risk 
factors that consist of several risk correlates of metabolic origin (Grundy, 2008).  It is a 
cluster of anthropometric, physiological and biochemical abnormalities linked together by 
poorly understood underlying mechanisms (Ford and Li, 2008).  
5 
 
A clustering of several metabolic risk factors was first described by Reaven, (1997)  a 
condition he called ‗syndrome x‘ which he also recognized as a multiplex factor for 
cardiovascular disease. Other researchers postulated that insulin resistance underlies 
syndrome X (Grundy et al., 2004), hence the commonly used term ‗insulin resistance 
syndrome‖. Syndrome x has also been referred to as the ‗plurimetabolic syndrome‘ (Reaven, 
1997)  or simply ‗metabolic syndrome‘. 
 
The World Health Organization (WHO) was the first to define the clinical criteria for the 
diagnosis of metabolic syndrome (Reaven, 2006; Zimmet et al., 2007; Grundy, 2008). The 
WHO report identified insulin resistance as the principal cause, making it necessary to 
identify its clinical indicators such as impaired glucose tolerance, impaired fasting glucose or 
insulin resistance for diagnosis (Grundy, 2008).  
 
The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) 
recognized the critical role of abdominal obesity in the pathogenesis of metabolic syndrome 
and replaced the need to demonstrate insulin resistance with an increased waist circumference 
(NCEP, 2002). There are many other definitions of metabolic syndrome such as that by the 
American Association of Clinical Endocrinologists (AACE), the International Diabetes 
Federation (IDF) and European Group for study of Insulin Resistance (EGSIR). 
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Of all these definitions, the NCEP ATP III is simpler to implement in research and clinical 
practice (Ford and Li, 2008; Parikh and Mohan, 2012). It also considers the proinflammatory 
and prothrombotic states as components of metabolic syndrome though they have not been 
included among the criteria necessary for its definition and diagnosis (Parikh and Mohan, 
2012).  
 
Based on the NCEP‘s findings the primary clinical outcome of metabolic syndrome is 
cardiovascular disease. The presence of any three of the following: central/abdominal obesity, 
high fasting triglycerides, high fasting blood glucose, low fasting HDL cholesterol and high 
blood pressure qualifies as metabolic syndrome (NCEP, 2002).  
 
There is an increasing incidence of metabolic dysfunction associated with metabolic 
syndrome. 
 
1.3 Prevalence of metabolic syndrome 
 
Two major factors account for an increase in the prevalence of metabolic syndrome (MS) 
worldwide; plentiful supply of inexpensive energy-packed foods and sedentary lifestyles. 
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Park et al., (2007)  reported a prevalence of 20% for MS among the US adult population 
emphasizing that it varies with ethnicity and is usually associated with modifiable risk factors. 
In a study involving 8608 participants aged less than 20 years, Ford and Giles, (2003)  
reported an age-adjusted prevalence of 23.9% using the ATP III criteria and 25.1% using the 
WHO criteria. A low prevalence of 1.2% was reported among young Jamaican adults in a 
cross-sectional study with a  16% prevalence for abdominal obesity and 47% for low HDL 
cholesterol (Ferguson et al., 2010). Among North Indian adolescents, a prevalence of 3.5% 
was reported using the ATP III criteria and 1.5% using the IDF criteria (Bhat et al., 2014),  
while in Korea an increase in age-adjusted prevalence of metabolic syndrome was noticed 
from 24.9% in 1998 to 31.3% in 2007 (Lim et al., 2011).  
 
In Africa, a high prevalence of MS has been observed. An urban population based study 
found a prevalence of 34.6% in Kenya (Kaduka et al., 2012), while Gyakobo et al., (2012)  in 
Ghana, reported a prevalence of 15% using the ATP III criteria and 35.9% according to the 
IDF criteria. A prevalence of 12.1 % was reported for a rural (Adegoke et al., 2010) and 18% 
for a semi-urban community (Ulasi et al., 2010) in Nigeria. In the Republic of South Africa, 
an age-adjusted  prevalence of 22.1% was reported  for a rural population with a higher 
prevalence in females ( 25.0%) than in males (10.5%) Motala et al., (2011).   
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1.4 Current treatment of metabolic syndrome 
 
The current treatment modalities for MS are directed at the management of the individual risk 
factors with a view to preventing the development of cardiovascular disease and type 2 
diabetes mellitus. While lifestyle and dietary modifications resulting in a modest weight loss 
could improve all the components of MS (Wagh and Stone, 2004), some patients may require 
drug therapy (Staels et al., 1998; Wagh and Stone, 2004). Some of the drugs used to manage 
the risk factors of metabolic syndrome include lipid lowering agents such as fibrates 
(fenofibrate and bezafibrate), statins and niacin (Jialal and Smith, 2012). Hypoglycaemic 
agents such as metformin, sulfonylureas and thiazolidinedion are used to control 
hyperglycaemia (Florez et al., 2014). These conventional drugs are not readily available and 
affordable to most communities in the developing world (Ayyanar et al., 2008). Medicinal 
plants which have already gained folkloric prominence in the management of many ailments 
including chronic non-communicable diseases therefore become an alternative (Fyhrquist et 
al., 2006).  
 
 Consequently, there is increasing global interest in research with the aim of finding and 
documenting scientific evidence to support the folkloric claims associated with these plants 
(Dillard and German, 2000).  Hibiscus sabdariffa is one of such plants that have received 
much research interest and is the plant of interest in this study. 
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1.5 Hibiscus sabdariffa 
 
Hibiscus sabdariffa (HS) is an  annual shrub which belongs to the Malvaceae family 
(Mahadevan et al., 2009; Maganha et al., 2010). It is called Roselle in English speaking 
countries while in North Africa, it is called karkade or carcade (Morton, 1987). It can be 
grown as a mono crop or mixed with other crops  (Da-Costa-Rocha et al., 2014). It is thought 
to be native to Asia or tropical Africa where it is grown as a garden crop. In Sudan HS is a 
major export crop (Leung and Foster, 1996; Gautam, 2004).  
  
Figure 1.1: Hibiscus sabdariffa plant in Sokoto, North West Nigeria (Photo taken by KG 
Ibrahim on 10/19/2014) 
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1.5.1 Botanical description 
 
HS belongs to the kingdom Plantae, division Angiosperms, class Eudicots, order Malvales, 
family Malvaceae, genus Hibiscus and species sabdariffa (Pfeil and Crisp, 2005). It can grow  
to 2.4 meters or more in height(Alarcon-Aguilar et al., 2007),  and has a deep penetrating tap 
root (Mahadevan et al., 2009). It has a smooth cylindrical, typically dark green to red stems 
(Leung and Foster, 1996; Maganha et al., 2010). The leaves are alternate, 7.5-12.5cm long, 
green with reddish veins and long petioles. The flowers are hermaphrodite and are insect 
pollinated (Mahadevan et al., 2009). It has a red calyx that consists of 5 large sepals with an 
epicalyx and bracteoles around the base (Da-Costa-Rocha et al., 2014). The capsule turns 
brown and splits open when it is matured and dry. The extracts of the calyx, stems and leaves 
are acidic (Julia, 1987; Ross, 2003; Da-Costa-Rocha et al., 2014).  
 
1.5.2 Traditional and economic uses of HS 
 
The different parts of the plant have many traditional uses in different communities across the 
world. 
 
 
 
11 
 
1.5.2.1 Uses of HS calyces 
 
Of the different parts of the plant, the calyces are the most extensively used for both 
traditional and medicinal purposes. Fresh and dried HS calyces are used in the preparation of 
hot or cold beverages (Babalola et al., 2001; Herrera- Arellano et al., 2004),  herbal drinks, 
fermented drinks, wine, jam, confectionaries, ice cream, chocolates, flavouring agents, 
puddings and cakes  (Gaya et al., 2009; Ojeda et al., 2010; Da-Costa-Rocha et al., 2014).  The 
calyces are boiled and processed into a local soft drink known as ―Sobo‖ in Nigeria 
(Mojiminiyi et al., 2012) or  ―agua de Jamaica‖ in Mexico (Alarcon-Aguilar et al., 2007).  
 
 Hibiscus sabdariffa calyces are used to treat cardiac and nerve ailments and also to induce 
diuresis (Da-Costa-Rocha et al., 2014; Patel, 2014). An infusion of the calyces has also been 
used to lower body temperature (Leung and Foster, 1996)  and to treat drunkenness (Morton, 
1987). Extracts of the  calyces  are also used in North Africa as a remedy for sore throats and 
cough as well as genital problems (Da-Costa-Rocha et al., 2014; Patel, 2014).  
 
12 
 
 
Figure 1.2: Dried calyces of Hibiscus sabdariffa (Photo taken by KG Ibrahim on 
08/20/2014) 
 
1.5.2.2 Hibiscus sabdariffa leaves 
 
The leaves of HS are consumed raw or cooked as a sour-flavoured vegetable or condiment 
(Ismail et al., 2008b). In Sudan and Malaysia they are eaten green or dried cooked with onions 
and ground nuts (Ismail et al., 2008b).  
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1.5.2.3 Hibiscus sabdariffa seeds 
 
The seeds of HS are eaten roasted or ground into meals (Wilson and Menzel, 1964). As 
powders, they are used in meals such as oily soups and sauces or as a substitute for coffee 
(Morton, 1987; Atta and Imaizumi, 2002). Hibiscus sabdariffa seeds are also used in the 
treatment of indigestion and dysuria (Morton, 1987), and for inducing or enhancing lactation 
(Gaya et al., 2009).  
 
1.5.3 Phytochemistry of HS calyces 
 
Hibiscus sabdariffa phytochemistry has been extensively studied and documented. For the 
purpose of this study, only the phytochemical composition of the calyces will be reviewed. 
 
1.5.3.1 Nutritional value of HS calyces 
 
The reported nutritional value of HS calyces differs between studies (see table 1.1). These 
differences could result from the variety of HS, soil type, harvesting and processing practices 
employed (Da-Costa-Rocha et al., 2014).    
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Table 1.1: Nutritional composition of HS calyces 
Nutrients (Mahadevan et al., 2009)  (Ismail et al., 2008a)  
Protein 1.145g/100g 1.9g/100g 
Fat 2.61g/100g 0.1g/100g 
Fibre 12.0g/100g 2.3g/100g 
Ash 6.90g/100g * 
Calcium 12.63mg/100g 1.72mg/100g 
Phosphorus 273.2mg/100g * 
Iron 8.98mg/100g 57mg/100g 
Carotene 0.029mg/100g 300µg/100g 
Thiamine 0.117mg/100g * 
Riboflavin 0.277mg/100g * 
Niacin 3.765mg/100g * 
Ascorbic acid 6.7mg/100g 14mg/100g 
Carbohydrates * 12.3g/100g 
*= not reported 
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1.5.3.2 Organic acid content of HS calyces 
 
Hibiscus sabdariffa calyces contain a high percentage of organic acids including citric acid, 
hydroxycitric acid, hibiscus acid, malic and tartaric acids as major organic acids and oxalic 
and ascorbic acid as minor organic acids (Mahadevan et al., 2009). The ascorbic acid content 
in the calyces varies between fresh (6.7-1.4mg/100g) (Morton, 1987; Ismail et al., 2008b)  and 
dried calyces (260-280mg/100g) (Ismail et al., 2008b).  
 
Hydroxycitric acid, hibiscus acid and its derivatives are the principal organic acids found in 
the calyces and leaves (Hida et al., 2007; Peng et al., 2011; Ramirez-Rodrigues et al., 2011b; 
Herranz-López et al., 2012). The hydroxycitric acid in HS calyces is the (+)- hydroxycitric 
acid also known as (+)-HCA (Yamada et al., 2007). Its Isomer (-)-HCA,  is an inhibitor of 
citrate lyase  (Sullivan et al., 1974b), and has been proposed as an anti-obesity agent (Sullivan 
et al., 1974a; Sullivan et al., 1974b; Hayamizu et al., 2003). In rats, hydroxycitric acid in HS 
calyx extract inhibits fat production from carbohydrates (Tee et al., 2002). It has been 
suggested that racemization of (+)-HCA to (-)-HCA by the intestinal flora may be an 
explanation to warrant the significant decrease in triacylglycerols in the experiment carried 
out on rats supplemented with HS calyx extracts (Carvajal-Zarrabal et al., 2009).  
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1.5.3.3 Anthocyanin content of HS 
 
The anthocyanins are a group of flavonoid derivatives and natural pigments present in the 
dried flowers of HS whose (anthocyanins) colour varies with pH (Da-Costa-Rocha et al., 
2014). These pigments have been researched extensively because of their recognized 
antioxidant activity (Alarcon-Alonso et al., 2012; Herranz-López et al., 2012).  
 
Yamamoto and Oshima, (1932)  identified the first anthocyanin from the calyces of HS 
―hibiscin‖ or ―hiviscin‖ to which they assigned the structure cyanidin-3-glucoside and then 
later renamed it to delphinidin-pentoside-glucoside (Yamamoto and Oshima, 1936). Other 
anthocyanins including  delphinidin-3-glucoside, cyanidin-3-glucoside (Shibata and 
Furukawa, 1969; Du and Francis, 1973) and cyanidin-3-sambubioside (gossipicyanin) 
(Shibata and Furukawa, 1969)  were also identified. Subramanian and Nair, (1972)  reported 
the presence of cyanidin-3, 5-diglucoside and cyanidin-3-(2G-glucosylrutinoside) in the 
flower pigments of HS. 
 
Several studies identified delphinidin-3-sambubioside and cyanidin-3-sambubioside as the 
major anthocyanins in HS calyx extracts (Alarcon-Aguilar et al., 2007; Beltrán-Debón et al., 
2010; Peng et al., 2011; Alarcon-Alonso et al., 2012; Herranz-López et al., 2012).  
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1.5.3.4 Flavonoid content of HS 
 
Hibiscus sabdariffa contains simple and polymerised forms of polyphenolic compounds   
(Da-Costa-Rocha et al., 2014). Hibiscitrin, sabdaritrin, gossypitrin, gossytrin, quarcetin, 
luteolin, chlorogenic acid, procatechuic acid, pelagonidic acid and eugenol have been 
described in HS extracts (Mckay, 2009). Alarcon-Alonso et al., (2012)  reported that the 
amount of quarcetin present in the aqueous extracts of HS calyces was 3.2mg/g while rutin 
was 2.1mg/g. Quarcetin and its conjugated glycosides as well as rutin were also identified in 
aqueous extracts of HS calyces together with kaempferol (Beltrán-Debón et al., 2010; 
Ramirez-Rodrigues et al., 2011a; Herranz-López et al., 2012).  
 
Aqueous calyx extracts of HS showed the presence of procatechuic acid (24.24%), catechin 
(2.67%), gallocatechin (2.44%), caffeic acid (19.85%) and gallocatechin gallate (27.98%) 
(Huang et al., 2009; Yang et al., 2009).  
 
Procatechuic acid (PCA), an important phenolic acid in the calyces of HS (Lee et al., 2002; 
Mckay, 2009), has been found to inhibit skin tumour promotion in mice (Tseng et al., 1998). 
Hibiscus sabdariffa calyces and leaves contain chlorogenic acid ; a phenolic (Salah et al., 
2002; Beltrán-Debón et al., 2010; Peng et al., 2011; Ramirez-Rodrigues et al., 2011a)  which 
belongs to a family of esters formed between certain tran-cinnamic and quinic acids (Clifford 
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et al., 2003). The amount of chlorogenic acid in HS extract was reported to be 2.7mg/g 
(Alarcon-Alonso et al., 2012).  
 
1.5.3.5 Polysaccharide content of HS 
 
Polysaccharides are present in large quantities in HS. Müller and Franz, (1992)  reported a 
yield of 10% reddish polysaccharides from ethanol-precipitated water extracts of HS calyces. 
Arabinose, galactose, glucose, rhamnose and smaller amounts of  mannose and xylose were 
identified in two different fractions (Müller and Franz, 1992; Brunold et al., 2004). The petals 
of HS yielded 65% (dry weight) of mucilage which yielded galactose, and rhamnose on 
hydrolysis (El-Hamidi et al., 1967).  
 
1.6 Pharmacology and biological activity of HS  
 
Hibiscus sabdariffa has been used in folk medicine in the treatment of many conditions and 
most of these folkloric claims have been verified scientifically. 
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1.6.1 Anti-obesity and hypolipidaemic effects 
 
The persistent increase in the global incidence of obesity is worrisome especially as it 
increases the risk of  developing  metabolic dysfunction (Villalpando-Arteaga et al., 2013b).   
Hibiscus sabdariffa has been proved to hold prospects in the prevention and treatment of 
obesity. 
 
Alarcon-Aguilar et al., (2007)  induced obesity in mice using monosodium glutamate (MSG) 
and then administered HS aqueous extracts for 60 days (33.64mg of total anthocyanins per 
120mg of extract) to healthy and obese mice. They observed significantly reduced body mass 
gain in obese mice and increased liquid intake in obese and healthy mice. While investigating 
the effects of HS ethanol extracts on fat-absorption-excretion and body weight in rats, 
Carvajal-Zarrabal et al., (2009)  concluded that components of HS at intermediate and greater 
concentrations could serve as anti-obesity agents. These anti-obesity effects could be as a 
result of the modification of the P13-K/Akt and ERK pathway which plays a vital role in 
adipogenesis (Kim et al., 2007).  
 
Lin et al., (2007)  investigated the effects of HS extract on serum cholesterol in human 
subjects and found that serum cholesterol was significantly reduced in subjects that took 2 
capsules (1g) of HS extract for a month suggesting that HS extracts may be effective in 
hypercholesterolaemic patients.  Hibiscus sabdariffa extracts (HSE) was also found to inhibit 
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serum lipids and to show anti-atherosclerotic activity (Chen et al., 2003). On histology, they 
found HSE to reduce foam cells formation and inhibit smooth muscle cell migration and 
calcification in the blood vessels of rabbits. Hibiscus sabdariffa extract (HSE) powder 
significantly reduced glucose and total cholesterol levels, increased TAG/HDL-c ratio, a 
marker of insulin resistance (Gurrola-Daiz et al., 2010).  
 
A reduction was observed in  the levels of LDL and the ratio of LDL-c to HDL-c when  HS 
extracts were administered to high fructose-fed and high cholesterol-fed rats; suggesting that 
it may be used to inhibit LDL oxidation and to prevent various types of hyperlipidaemia in 
high fructose-fed and high cholesterol- fed rats (Chen et al., 2004). Aqueous calyx extracts of 
HS inhibit the accumulation of triglycerides better when the fibre and polysaccharide 
components have been removed (Herranz-López et al., 2012).  
 
1.6.2 Antihypertensive and cardioprotective effects 
 
Hypertension contributes significantly to the global burden of non-communicable diseases 
and is responsible for  a lot of morbidities and mortalities (Wahabi et al., 2010). Annually 
hypertension accounts for about 13% of deaths globally (Brown, 1997). Hibiscus sabdariffa 
has been shown to have anti-hypertensive effects in animals (Onyenekwe et al., 1999; Odigie 
et al., 2003; Mojiminiyi et al., 2007; Inuwa et al., 2012; Mojiminiyi et al., 2012)  and humans 
(Haji-Faraji and Haji-Tarkhani, 1999; Herrera- Arellano et al., 2004; Mckay, 2009; 
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Mozaffari-Khosravi et al., 2009). Its antihypertensive effect is thought to be mediated via a 
direct vaso-relaxant effect (Adegunloye et al., 1996; Onyenekwe et al., 1999; Ali et al., 2005),  
diuretic(Cáceres et al., 1987; Onyenekwe et al., 1999; Mojiminiyi et al., 2000), calcium ion 
channels modulation (Owolabi et al., 1995) and the inhibition of angiotensin converting 
enzyme by the anthocyanins (Ojeda et al., 2010).  
 
Hibiscus sabdariffa has been found to exhibit cardio-protective activity by enhancing 
myocardial capillarization in spontaneously hypertensive rats that were orally fed its aqueous 
calyx extracts (Inuwa et al., 2012), and by reversing cardiac hypertrophy in 2K-1C (2Kidneys, 
1 clip) hypertensive rats (Odigie et al., 2003).  
 
1.6.3 Anti-diabetic effects 
 
Diabetes mellitus is an endocrine disorder associated with hyperglycaemia, dyslipidaemia and 
results from defects in insulin secretion and/or action (Alberti and Zimmet, 1998; Da-Costa-
Rocha et al., 2014). Globally, diabetes mellitus is a highly prevalent disease responsible for 
high morbidity and mortality (Peng et al., 2011). When HS polyphenolic extract was 
administered to a type 2 diabetic rat model at a dose of 200mg.kg
-1
 it reduced 
hyperglycaemia, hyperinsulinaemia, advanced glycation end product and lipid peroxidation 
(Peng et al., 2011). Hibiscus sabdariffa was shown to be a potent inhibitor of pancreatic  α-
amylase (Adisakwattana et al., 2012). The inhibition of pancreatic α-amylase and intestinal α-
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glucosidase slows down the digestion of carbohydrates to more absorbable monosaccharides; 
a therapeutic strategy currently in vogue for the control of post prandial hyperglycaemia 
(Adisakwattana et al., 2012). The hypolipidaemic and antioxidant properties of HS ethanolic 
extract were confirmed in alloxan-induced diabetic rats (Farombi and Ige, 2007)  where they 
showed therapeutic potentials in preventing the development of atherosclerosis and other 
cardiovascular complications associated with diabetes. Similarly, Huang et al., (2009)  
reported that a polyphenolic extract of HS suppressed the high-glucose stimulated cell 
proliferation and migration in a dose and time dependent manner. 
 
1.6.4 Anti-oxidant effects 
 
Antioxidants protect the tissues from peroxidative damage (Halliwell, 1997; Olaleye, 2007). 
Several studies have reported the antioxidant activity of HS (Farombi and Fakoya, 2005; 
Hirunpanich et al., 2005; Usoh et al., 2005; Christian, 2006; Olaleye and Rocha, 2007; Mohd-
Esa et al., 2010; Mossalam et al., 2011). This antioxidant activity is expressed in different 
ways and by both aqueous and ethanolic extract of the calyces, seeds and leaves (Mohd-Esa et 
al., 2010). The extract can exert their antioxidant action by scavenging free radicals and 
reactive oxygen species (Tseng et al., 1998; Farombi and Fakoya, 2005; Usoh et al., 2005),  
inhibition of xanthine oxidase activity (Tseng et al., 1998)  and prevention of cell damage via 
lipid peroxidation (Farombi and Fakoya, 2005). Hibiscus sabdariffa extracts also inhibit the 
formation of malonyldialdehyde (Farombi and Fakoya, 2005; Usoh et al., 2005)  and 
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oxidation of low density lipoprotein and formation of thiobarbituric reactive substances 
(TBARS) by Cu
2+
 (Hirunpanich et al., 2005). Hibiscus sabdariffa could reduce glutathione 
depletion and also alter the activities of superoxide dismutase and catalase in the liver and 
blood (Usoh et al., 2005).  
 
1.6.5 Hepatoprotective effects 
 
Lee et al., (2012)  found that pre-treatment with a polyphenolic extract of HS protected the 
liver from acetaminophen-induced liver injury in BALB/c mice. The extracts increased the 
level of glutathione, decreased the level of peroxidation and increased catalase activity in the 
liver. 
 
Hibiscus sabdariffa also reduced liver steatosis and fibrosis, decreased the elevation of 
aspartate aminotransferase (AST) and alanine aminotransferase (Liu et al., 2006). During 
Carbon tetrachloride (CCl4) treatment, HS extracts restored the decrease in glutathione 
content and inhibited lipid peroxidation (Liu et al., 2006).  
 
Hibiscus sabdariffa aqueous extract was found to reduce body mass gain and protect the liver 
by reducing fat accumulation, attenuating steatosis, down-regulating sterol regulatory element 
binding protein (SREBP-1c) and peroxisome proliferator- activated receptor gamma (PPAR-
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γ), blocking the increase of interleukin one (IL-1), tumour necrosis factor alpha messenger 
ribonucleic acid (TNF-α  mRNA), lipoperoxidation and increasing  catalase mRNA in obese 
C57BL/6NHsd mice (Villalpando-Arteaga et al., 2013b).  
 
1.6.6 Nephroprotective effects 
 
 Most often diabetic nephropathy progresses to end stage renal disease and this is thought to 
be mediated by oxidative stress (Lee et al., 2009). Phenolic extracts of HS reduced the kidney 
mass and improved the hyperglycaemia-induced osmotic diuresis in the proximal tubules 
while significantly lowering the serum triglyceride, total cholesterol, LDL and increasing the 
activity of catalase, glutathione and reducing lipid peroxidation in streptozotocin-induced 
diabetic rats (Lee et al., 2009). These findings were in agreement with those of Wang et al., 
(2011) . The latter proposed that the observed HS extracts nephroprotective effects might 
involve the up-regulation of Akt/Bad/14-3-3γ and nuclear factor-kappa B (NF-κB)-mediated 
transcription.  In a study on the effects of HS calyces on creatinine and serum electrolytes, no 
significant harmful changes were observed in blood urea nitrogen (BUN), serum creatinine, 
sodium and potassium levels (Mohagheghi et al., 2010).  
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1.6.7 Anti-cancer effects 
 
Hibiscus sabdariffa protocatechuic acid was found to inhibit the 12-O-tetradecanoylphorbol-
13-acetate (TPA)-induced promotion in skin tumours of female CD-1 mice (Tseng et al., 
1998). The topical application of protocatechuic acid twice weekly prior to TPA treatment 
inhibited the incidence of tumours in mice significantly while all the mice that were not 
treated developed the tumour. 
 
In an in vitro study, HS anthocyanins were found to induce apoptosis in cancer cells 
especially in human promyelocytic leukaemia  (HL-60) cells using promyelocytic leaukemic 
cells (Chang et al., 2005). A polyphenol-rich extract of HS was also found to induce apoptosis 
in human gastric carcinoma cells by causing DNA fragmentation with an increase in the 
distribution of the hypodiploid phase (Lin et al., 2005). This action is thought to be mediated 
via tumour protein 53 (p53) phosphorylation and p38 mitogen-activated protein kinase/ Fas 
Ligand (MAPK/FasL) cascade pathway (Lin et al., 2005).  
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1.6.8 Anti-pyretic effects 
 
Hibiscus sabdariffa calyx aqueous and ethanolic extracts were investigated for their 
nociceptive, anti-inflammatory and anti-pyretic effects using the writhing, hot plate and 
formalin tests in mice; yeast-induced fever and carrageenaan-induced paw oedema in rats 
respectively (Reanmongkol and Itharat, 2007). The ethanol and vacuum dried extracts of HS 
(200-800mg.kg
-1
) reduced the yeast-induced fever but had no effect on the other tests 
suggesting that HS calyx extracts have anti-pyretic effects through mechanisms different from 
those of aspirin (Reanmongkol and Itharat, 2007).  
 
1.6.9 Sexual maturity and lactogenic effects   
 
Hibiscus sabdariffa aqueous  extracts administered to pregnant  Sprague Dawley rats  resulted 
in post natal weight gain in the pups, delayed onset of puberty in the female offspring and 
increased body mass index through mechanisms that may be linked to glucocorticoid and 
leptin signalling  (Iyare and Adegoke, 2008; Iyare and Nwagha, 2009). Gaya et al., (2009)  in 
a lactogenic study on the seeds of HS  found an elevation in the serum prolactin levels of 
Albino Wistar rats in a dose dependent manner with the maximum effect occurring at doses of 
800mg.kg
-1
 and 1600mg.kg
-1
. 
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1.6.10 Anti-bacterial effects  
 
Methanolic extracts of HS were studied for their antimicrobial effects in vitro using a disc-
diffusion method. The extracts exhibited activities comparable to that of streptomycin against 
various clinically important gram positive and gram negative bacteria such as  Staphylococcus 
aureus,  Micrococcus luteus, Clostridium sporogens, Escherichia coli, Klebsiella 
pneumonaie, Bacillus cereus and Pseudomonas fluorescence (Olaleye, 2007). Fullerton et al., 
(2011)  investigated the antimicrobial effects of HS calyces against Escherichia coli O157:H7 
found in food, veterinary and clinical samples. The calyx extracts of HS exhibited 
antimicrobial action against Escherichia coli at 2.5%, 5% and 10 % concentrations. 
 
1.6.11 Effects on smooth muscles 
 
An aqueous extract of the petals of HS was shown to have a vaso-relaxant effect on rat aortic 
rings through endothelium-dependent and independent mechanisms (Obiefuna et al., 1994).  
Fouda et al., (2007)  reported an inhibition of rat bladder and uterine contractility by an 
aqueous calyx extract of HS through mechanisms unrelated to local or remote autonomic 
receptors or calcium channels as previously suggested in a study of the effects of HS on the 
GIT (Salah et al., 2002).  
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1.6.12 Haematenic effects 
 
The dried fermented calyces of HS have a very low pH (3.2) which increases the 
bioavailability of other minerals such as iron and calcium (Falade et al., 2005). The high 
ascorbic content of HS calyces could also be responsible for an increase in the bioavailability 
of other minerals including iron which are essential for erythropoesis (Falade et al., 2005).  
There may therefore be a role for HS in iron supplementation in the prevention or treatment of 
anaemia. Adigun et al., (2006)  studied the effects of HS extracts on some haematological 
parameters in Wistar albino rats. After 14 days of HS oral administration, a significant 
elevation of haematocrit and haemoglobin in the groups that received low doses of the extract 
(200mg.kg
-1
 body wt. and 400mg.kg
-1
 body wt.) was observed while the groups that received 
higher doses had significant reduction in haematocrit but not haemoglobin concentration. 
 
1.6.13 Other effects 
 
Hibiscus sabdariffa aqueous extracts were shown to possess diuretic and natriuretic properties 
via the compound quarcetin which causes the vascular endothelium to release nitric oxide and 
cause renal vasodilation and increased kidney filtration in rats (Alarcon-Alonso et al., 2012).  
Hibiscus sabdariffa extracts were also suggested as a valuable ethnomedicine in the 
management of chronic inflammatory diseases because of its ability to modulate the 
production of monocyte chemoattractant protein-1 (Beltrán-Debón et al., 2010). This 
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immunomodulatory action might be both cell and humoural mediated (Fakeye et al., 2008).  
There is also evidence for use of aqueous dried calyx extracts as an anti-diarrhoeal agent  as it 
was found to increase transit time and reduce intestinal motility in rats (Owulade et al., 2004).  
1.7 Toxicological aspects of HS plant 
 
 Hibiscus sabdariffa has been investigated extensively to determine its safety. An LD50 of 0.4-
0.6ml (120-180mg) for a 30% aqueous extract of HS was reported by Sharaf, (1962)  during 
an intraperitoneal administration in mice. In an acute toxicity test using the method of Lorke, 
Onyenekwe et al., (1999)  observed no deaths in the experimental mice fourteen days after 
intraperitoneal administration of 1000-5000mg.kg
-1
  body weight of the HS calyx extract and 
calculated an LD 50 greater than 5000mg.kg
-1.
 While investigating the antihypertensive 
effects of HS in spontaneously hypertensive rats, using the Wistar Kyoto rats as controls, 
sudden deaths of all the hypertensive rats by day 21 of continuous administration of the HS 
extracts at a dose of 1000mg.kg
-1 
body weight was observed (Onyenekwe et al., 1999). The 
authors concluded that the sudden deaths of the animals could have been due to the diuretic 
effect of the extracts. An LD50 of > 5000mg.kg
-1
 was reported in acute toxicity studies in 
albino mice for a methanolic dried flower extract (Ndu et al., 2011)  and during a 
toxicological and lactogenic study in Albino Wistar rats (Gaya et al., 2009).  
 
While investigating the toxicology of an aqueous-methanolic extract of HS calyces, 
Akindahunsi and Olaleye, (2003)  administered 250mg.kg
-1
 body mass per day of the extract 
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to six groups of Wistar albino rats (0,1,3,5,10 and 15 doses per day). The rats in all the 
treatment groups showed increased activities of serum aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT) but not alkaline phosphatase (ALP) and lactate 
dehydrogenase (LDH) when compared to the control group that had received normal saline. 
They concluded that consumption of doses of HS between 150-180mg.kg
-1
 per day appeared 
safe while higher doses could affect the liver. 
Feeding of pregnant Sprague Dawley rats with an aqueous calyx extract of HS resulted in a 
decrease in food and fluid intake, decrease in litter size, increased birth mass  but had no 
effect on the length of gestation (Iyare and Adegoke, 2008; Iyare and Nwagha, 2009).  
However chronic administration of high doses of HS up to 4600mg.kg
-1
 have been associated 
with histopathological changes in the testes and increased serum creatinine levels  (Orisakwe 
et al., 2004; Fakeye et al., 2009). Considering the above data, there is a need for further 
studies on the safety or otherwise of HS extracts. 
 
1.8 Justification of the study 
 
Hibiscus sabdariffa is a plant with multiple ethnomedicinal uses. The beverages made from 
its calyces are consumed by all age groups in Nigeria and most tropical countries where it is 
produced. The seeds of HS are also used to induce or enhance lactation (Gaya et al., 2009).  
Neonatal exposure can occur directly when the neonates are fed with the beverage or 
decoctions of HS for medicinal reasons or indirectly via the mother‘s milk. 
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As is the case for most other nutraceuticals, HS is consumed orally; consequently the GIT is 
its first point of contact with the body. Having in mind that the neonatal GIT is highly 
susceptible to structural and functional changes most especially during the suckling period 
which could be perpetuated throughout life (Pacha, 2000)  and that certain plant extracts could 
cause accelerated structural and functional maturation of  the neonatal GIT (Linderoth et al., 
2005; Beya et al., 2012; Dangarembizi et al., 2014), it becomes imperative to study the effects 
of HS on the developing GIT. 
 
Previous studies on the extracts of HS have been focused on adults and usually sought to 
determine its phytochemistry, pharmacology or toxicity but not its capacity to be used as a 
preventive intervention. There is an increasing incidence of metabolic syndrome and its 
complications  worldwide (Armitage et al., 2004)  with a horrifying increase in childhood 
obesity and its sequelae (Ebbeling et al., 2002). These tendencies are associated with altered 
lifestyle and dietary changes (Armitage et al., 2004). There is abundant evidence to suggest 
that the antenatal and early post natal environment can influence health outcomes later in life 
(Patel and Srinivasan, 2002; Armitage et al., 2004; Moura and Passos, 2005). This 
phenomenon is referred to as neonatal programming. 
 
Several studies using the neonatal rat model (Linderoth et al., 2005; Erlwanger and Cooper, 
2008; Beya et al., 2012; Dangarembizi et al., 2014)  have speculated on the perpetuation of 
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the changes they observed through to adulthood and whether they would confer any benefit to 
the animals later in life. 
 
In this present study, I aimed to provide data on the effects of HS on the morphometry of the 
neonatal GIT, growth performance, metabolic substrates and general health; and to explore 
whether the early administration of HS in the suckling period will have any effect in the 
response of the animals to a high fructose diet during the adolescent period. 
 
The 4-day old neonatal Sprague Dawley rat pups were used to model the human neonate 
while the weanling rats were used to model the growing child in this study that was done in 
two phases. 
 
1.9 Aims and objectives of the study 
 
The main objective of this study was to determine the effect of administration of aqueous 
calyx extracts of HS on the gastrointestinal tract, growth performance, metabolic substrates 
and biochemical markers of health in the neonatal rat; and to investigate whether it would 
confer any protection or predisposition to the development of diet-induced metabolic 
dysfunction in the growing period. 
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The study aimed to specifically determine: 
a.  the growth performance of the rats through the measurement of body weight gain, 
linear growth by determining the lengths and masses of the tibiae and femur. 
b.  glucose tolerance in the rats (phase 2). 
c.  the plasma concentration of insulin and determination of the homeostatic model of 
insulin resistance (HOMA-IR) in phase 2.    
d.  circulating metabolic substrates (glucose and triglycerides). 
e.  hepatic storage of lipids and glycogen.  
f.  the morphology of the GIT and other viscera by gross measurement of their  lengths 
and masses  and histological assessment of the small intestines (phase1). 
g.  biochemical markers of health by measuring in plasma.   
-  levels of alanine aminotransferase (ALT) and  alkaline phosphatase (ALP) as 
surrogate markers of liver function. 
-  levels of Blood Urea Nitrogen (BUN) and creatinine as surrogate markers of renal 
function. 
-total bilirubin, globulin, calcium, phosphorus, total protein, albumin, total cholesterol, 
and amylase. 
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h.  the plasma concentration of thiobarbituric acid reactive substances as a measure of 
lipid peroxidation (phase 2). 
i.  the gender-based differences in all the above measured parameters in both the neonatal 
(phase 1) and the growing rats (phase 2). 
 
1.10 Hypotheses 
 
For phase 1 
Ho: Aqueous calyx extracts of HS do not affect the gastrointestinal tract, growth performance, 
metabolic substrates and biochemical markers of health of suckling rat pups. 
H1: Aqueous calyx extracts of HS affect the gastrointestinal tract, growth performance, 
metabolic substrates and biochemical markers of health of suckling rat pups. 
 
For phase 2 
Ho: Aqueous calyx extracts of HS administered in the suckling period (preweaning) do not 
affect the response of Sprague Dawley rats to the inclusion of a high concentration of fructose 
in their diet post weaning. 
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H1: Aqueous calyx extracts of HS administered in the suckling period affect the response of 
weanling Sprague Dawley rats to the inclusion of a high concentration of fructose in their diet 
post weaning.
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CHAPTER TWO: EFFECTS OF 
HIBISCUS SABDARIFFA AQUEOUS 
CALYX EXTRACTS ON THE GROWTH 
PERFORMANCE, GASTROINTESTINAL 
TRACT MORPHOMETRY AND 
METABOLIC SUBSTRATES OF 
SUCKLING RATS 
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2.1 Introduction  
As previously mentioned, the gastrointestinal tract serves as the first point of contact for 
nutraceuticals, being that they are mostly ingested orally. Hibiscus sabdariffa decoctions for 
the purpose of beverage or tea are also taken orally. In Nigeria and most tropical areas, HS is 
consumed by all age groups. The seeds of HS are used to induce lactation and improve milk 
let-down in some communities (Gaya et al., 2009). The neonatal GIT is susceptible to 
structural and functional changes when it is exposed to certain dietary constituents especially 
during the critical periods of gestation and lactation when there is relative plasticity of the 
tissues (Pacha, 2000). Plant extracts can cause precocious maturation of the gut (Linderoth et 
al., 2005). Artificial milk has also been shown to cause a similar effect (Dvorak et al., 2000).    
 
Many peptides that regulate metabolic function in the body originate from the GIT (Sorensen 
et al., 2010). Therefore any insult that affects the GIT will also likely affect the availability of 
these peptides and consequently affect the growth performance and uptake of metabolic 
substrates in the neonate. Considering that there is exposure of the neonatal GIT to HS 
extracts either directly or indirectly through the breast milk, it becomes imperative to study 
and document its effects.  
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2.1.1 The gastrointestinal tract 
 
The GIT is a specialised system that serves as a link between the body and the outside 
environment, allowing for food to be digested and absorbed for the benefit of the individual 
(Schneeman, 2002). At birth, the GIT undergoes changes to enable it cope with the shift from 
the parenteral placental nutrition to enteral nutrition  (Sangild et al., 2000). Most of the 
development of the  human GIT occurs in utero during the weeks leading to parturition but 
full functions of some organs especially the intestines are not attained until the age of 2 years 
(Sangild et al., 2000; Corpeleijn et al., 2008). The GIT performs very important functions in 
the overall regulation of body homeostasis including among others: digestion and absorption 
of nutrients, metabolism and immune response (Baltrop and Brueton, 1990). For effective  
distribution of nutrients to various organs and also for control of food intake and utilisation, 
the GIT is connected with other systems of the body such as the cardiovascular and central 
nervous systems (Schneeman, 2002).   
 
The neonatal GIT allows for selective pinocytosis of macromolecules during the suckling 
period which permits  passage of maternal antibodies to the pups for protection (Linderoth et 
al., 2005). This ability is however lost as the enterocytes attain adult configuration and gut 
closure occurs at 3 weeks under the influence of glucocorticoids (Henning, 1986). The 
structure of the GIT is composed of four specialised layers: the mucosa, sub-mucosa, 
muscularis and each of the layers adapted to particular  functions (Xu, 1996). The mucosa 
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comes in direct contact with the external environment and its structural and functional 
integrity determines its absorptive capacity, nutrient availability and therefore health and 
wellbeing of the individual (Buddington and Kimura, 2003). In the small intestines, the 
mucosa is thrown into folds called villi which are covered by enterocytes that originate from 
the crypts and differentiate as they migrate to the villi tip (Baltrop and Brueton, 1990). The 
GIT mucosa is a major source of peptides such as ghrelin and cholecystokinin which regulate 
metabolic and digestive functions in the body (Sorensen et al., 2010). It therefore follows that 
interference with the integrity of the GIT mucosa affects the secretion of these peptides with 
consequences on the metabolism of the organism. 
 
2.1.2 Phytochemicals and health 
 
Phytochemicals are plant components that possess biological activities (Farombi., 2003). 
They affect the metabolism and physiology of the individual when ingested (Dillard and 
German, 2000; Liu, 2007). Most of these phytochemicals are incorporated into food and 
pharmaceutical products as nutraceuticals. Nutraceuticals are non-toxic food extract 
supplements that have been scientifically proved to have health benefits in both prevention 
and treatment of diseases (Dillard and German, 2000; Holst and Williamson, 2008).  
Phytochemicals are broadly classified into three groups: terpenoids, phenolics and alkaloids 
and other nitrogen-containing constituents (Harborne, 1999). Some phytochemicals such as 
anthocyanins have been shown to have antioxidant and anti-mutagenic properties (Dillard and 
  
40 
 
German, 2000). Phytochemicals affect the general health of the body in a number of ways 
which could either be beneficial or detrimental. They could act as substrates for biochemical 
reactions, co-factors of enzymatic reactions, enzyme inhibitors and as absorbents that bind to 
and help in eliminating unwanted materials from the GIT (Dillard and German, 2000; Bagchi 
et al., 2011). Phytochemicals could also act as agonists or antagonists of biological receptors, 
scavengers of toxic substances or as enhancers of absorption of essential nutrients (Dillard 
and German, 2000). Hibiscus sabdariffa has an abundance of phytochemicals (as discussed in 
chapter one) which could affect the general health of individuals consuming it either for 
medicinal or nutritional purposes.  
 
2.1.3 Hibiscus sabdariffa and the GIT 
 
Only two studies were found that investigated the effects of HS on the GIT. Hibiscus 
sabdariffa aqueous (Owulade et al., 2004)  and methanolic (Salah et al., 2002)  extracts were 
found to increase intestinal transit time and inhibit intestinal motility in adult rats. The 
flavonoids,  quercetin and eugenol were postulated to be responsible for these effects via 
modulation of Ca
2+
 channels (Salah et al., 2002).  
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2.2 Materials and methods 
 
2.2.1. Study setting  
 
The study was conducted from 2013 to 2014 at the Central Animal Services facility and the 
School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, 
Johannesburg, Republic of South Africa. 
 
2.2.2. Ethics clearance 
 
All the protocols used in the study were approved by the Animal Ethics Screening Committee 
of the University of the Witwatersrand, Johannesburg (AESC/2013/46/05) with subsequent 
modifications (appendices 1, 2 and 3). 
 
2.3 Materials 
 
2.3.1 Source of HS Calyces 
 
Dried calyces of HS were purchased at the central market in Sokoto, North West Nigeria. 
They were authenticated by Mr. Halilu E. Mshelia of the department of Pharmacognosy and 
Ethnopharmacy, Faculty of Pharmaceutical Sciences, Usmanu Danfodiyo University, Sokoto 
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and a voucher specimen was deposited at the departmental herbarium 
(PCG/UDUS/Malv/0001). The dried calyces were then imported into RSA to the University 
of the Witwatersrand, Johannesburg where they were further processed and the animal studies 
were conducted.  
 
2.4 Methods 
 
2.4.1 Preparation of the calyx extracts 
 
The dried calyces were ground to a fine powder using a Waring blender (Waring
®
, USA). 
Two hundred and ten grammes of the calyx powder were extracted in 1400ml of distilled 
water at 95ºC for 2 hours (Lin et al., 2007). The extracted solution was then filtered through 
Whatman 1 filter paper and the filtrate was concentrated using a rotor evaporator (Labocon 
(Pty) Ltd, Krugersdorp, South Africa). The concentrated suspension of the extracts was then 
dried in an oven (Salvis®, Salvis Lab, Schweiz, Switzerland) at 40ºC  (Dangarembizi et al., 
2014)  and the residual powder extracts were recovered and stored in dark, tightly sealed glass 
vials at 4ºC  for future use (Ali et al., 2003; Lin et al., 2007).  The recovered powder weighed 
22% of the starting calyces. 
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2.4.2 Study animals 
 
Forty two, 4-day old, suckling Sprague Dawley pups from four dams that were sourced from 
the Central Animal Services, University of the Witwatersrand, were used in the study. 
 
2.4.3 Housing and care of the animals 
 
Each dam and its litter were housed in Perspex cages lined with wood shavings. The dams 
were supplied with standard rat cubes (Epol
®
, Johannesburg, South Africa) and tap water ad 
libitum. The room temperature was maintained at 26±2ºC and a 12 hr light cycle followed 
(lights on 07.00hrs- 19.00hrs).  The pups were allowed to nurse freely with their dams 
throughout the duration of the study. 
 
2.4.4 Study design 
 
The birth day of the pups was designated day zero (Erlwanger and Cooper, 2008)  and on day 
4, the pups in each litter were randomly assigned to three treatment groups (in a split litter 
manner) which  were distinctly identified using unique, non toxic colour-coded markings on 
their tails.  The first group, the control group (n=14, 7 males and 7 females) received distilled 
water at 10ml.kg
-1
 BM, Group 2 (n = 14, 7 males and 7 females) received a low dose of HS 
extract (50mg.kg
-1
) while the third group (n = 14, 7 males and 7 females) received a high dose 
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of the extracts (500mg.kg
-1
). The treatments were administered once daily in the morning 
(08.00hrs-09.00hrs) via oral gavage using an orogastric tube mounted on a 1ml syringe 
(Erlwanger and Cooper, 2008; Beya et al., 2012; Dangarembizi et al., 2014)  for 9 consecutive 
days till post natal day 14. This was to prevent the compounding effects on the HS treatment 
that could result due to exploratory feeding of the pups after they open their eyes on postnatal 
day 14. The doses of HS used in this study were within the ranges used by other researchers 
without recording adverse effects on health (Onyenekwe et al., 1999; Gaya et al., 2009; Ndu 
et al., 2011).   
 
2.4.5 Body mass measurements 
 
The pups were weighed daily on  a balance (Snowrex Electronic Scale, Clover Scales, 
Johannesburg) in order to adjust the amount  of  aqueous HS calyces extract administered so 
as to maintain a constant dose and also to monitor their growth performance. The dams were 
weighed weekly as part of routine health monitoring. 
2.4.6 Terminal procedures 
 
2.4.6.1 Termination of pups 
 
On post natal day 14, blood was obtained from the pups via a pin prick of the tail and used for 
determination of non-fasting glucose with a calibrated glucometer (Ascensia Elite
TM
 Blood 
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glucose meter, Bayer Corporation, Mishawaka, USA). Thereafter, the pups were euthanased 
by intraperitoneal anaesthetic overdose of sodium pentobarbitone (Eutha-naze, Bayer, 
Johannesburg, South Africa) at 200mg.kg
-1 
body mass.  
 
2.4.6.2 Collection of blood, plasma processing and storage 
 
Following euthanasia, the thorax was opened and blood was collected via cardiac puncture 
with 21G needles and 5ml syringes. The blood was immediately transferred to lithium-heparin 
blood tubes (Becton Dickinson Vacutainer Systems Europe, Meylan Cedex, France) which 
were gently inverted to ensure proper mixing with the anticoagulant. The blood was then 
centrifuged at 4000 x G for 15 minutes at 20ºC in a centrifuge (SorvalIIRT®6000B, DuPont 
Instruments, New York, USA). Plasma was stored in microtubes (Eppendorf, Hamburg, 
Germany) at   - 20ºC in a freezer (Bosch, Johannesburg, South Africa) until needed for assay 
of the biochemical markers. 
 
2.4.6.3 Morphometry of the GIT and other viscera 
 
Through a midline incision, the abdomen was opened. The GIT and liver were carefully 
dissected out. The contents of the stomach, small intestines, large intestines and caecum were 
gently emptied. Both the GIT and the above mentioned viscera were weighed with an 
electronic balance (Presica 310M, Presica Instruments AG, Switzerland) and recorded. As 
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described in similar studies (Erlwanger and Cooper, 2008; Beya et al., 2012; Dangarembizi et 
al., 2014) the small and large intestines were gently stretched on a cool dissecting board on 
which a ruler was mounted, and their lengths were recorded. The liver was preserved in a 
freezer (Haier Biomedical, China) at -20ºC for future determination of hepatic storage of 
lipids and glycogen. 
 
2.4.6.4 Determination of long bone parameters 
 
The right hind legs from the carcasses were carefully dissected and detached from the 
acetabulum using a pair of scissors and scalpel blade which were also used to meticulously 
clean the femur and tibia of all non-bony tissues. The bones were then dried in an oven 
(Salvis 
®
, Salvis Lab, Switzerland) at 50ºC for 5 days until uniform mass was achieved. This 
was to remove any moisture content from the bones since the carcasses were initially stored in 
a freezer (Haier Biomedical, China) before the bones were dissected out at a later date. This 
dry mass, together with the bone length determined using a vernier calliper (Hi-impact, 
Dejuca, South Africa) were used to calculate the bone density. The bone density was 
calculated using the formula: 
Bone density= mass of the bone (mg)/length of the bone (mm) (Monteagudo et al., 1997)  
 
 
  
47 
 
2.4.6.5 Hepatic storage of metabolic substrates 
 
2.4.6.5.1 Quantification of hepatic lipid stores 
 
The hepatic storage of lipids was determined using a solvent extraction method as described 
by Bligh and Dyer, (1959) . Essentially, 300-500mg of liver sample was placed in 150ml of 
2:1 chloroform: methanol solution and allowed to extract overnight at 4ºC. The solution was 
then filtered through filter paper (Whatmann®, No 1, size 185 mm, pore size 7-11μm, 
England) into separation funnels where 30ml of 0.9% saline was added to the filtrate from a 
dispensing bottle. The separation funnels containing the solutions were kept overnight at 4ºC 
to allow separation into two phases. The bottom phase was collected into round bottom flasks 
and evaporated to dryness under vacuum with a rotor evaporator (Labocon (pty) Ltd, 
Krugersdorp, South Africa) at 37ºC. 20ml of chloroform was then added to make up the stock 
solution from which an aliquot of 2ml was taken, placed in dried, pre-weighed 10ml 
scintillating bottles and dried in an oven (Salvis®, Salvis Lab, Schweiz, Switzerland) at 50ºC  
for 30 minutes. The scintillating bottles were then re-weighed and the percentage lipid content 
was then calculated as follows: 
% liver lipids = total mass of the lipids/mass of the sample x 100. 
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2.4.6.5.2 Quantification of hepatic glycogen stores 
 
The liver glycogen stores were determined indirectly by hydrolyzing the glycogen to glucose 
and then determining the concentration of glucose as described by Passonneau and 
Lauderdale, (1974). Briefly, 0.1g of the liver sample was placed in a test tube and 
homogenized (Ultra turrax
®
 homogenizer, Janke and Kunkel, Germany) in 1ml of 0.03M 
HCl.  Into the homogenized liver was added 1ml of 1M HCl. The sample was then thoroughly 
mixed using a vortex mixer (Vortex mixer WM-300, Cannic Inc. USA), sealed and then 
placed in a boiling water bath for 2 hours to hydrolyse the glycogen. Thereafter, 1ml of 1M 
NaOH was added to the sample and mixed with the vortex mixer to neutralize the acid. The 
concentration of glucose in the hydrosylate was then determined colorimetrically with a 
glucometer (Accu-Chek Active, Roche, Germany) and the result expressed as glucose 
equivalents in the homogenate. 
 
2.4.6.6 Determination of clinical biochemical markers of health  
 
A total of thirteen parameters were measured using a VetTest analyser (IDEXX VetTest® 
Clinical Chemistry Analyser, IDEXX Laboratories Inc., USA) to determine the effects of HS 
administration on the health profile of the study animals. The machine is a colorimetric 
chemistry analyser and was calibrated according to the manufacturer‘s instructions before the 
assay. Plasma samples that had previously been frozen were thawed, warmed to room 
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temperature and gently agitated for uniform mixing of the sample. A pipette that was attached 
to a probe from the analyser sucked up 150µl of the plasma and deposited it on the pre-loaded 
discs. The samples were then analysed and a print out of the results was retrieved from the 
machine. 
 
2.5 Statistical analysis  
 
All data from the study was expressed as mean ± standard deviation. Data was analysed using 
Graph pad Prism version 5 (Graph-pad Software Inc., San Diego, USA). The level of 
significance was set at p≤0.05. A one way analysis of variance was used to assess the effects 
of HS extracts on the parameters measured. This was followed by a Bonferroni post hoc test 
for comparison of the means. 
 
2.6 Results  
 
There were no gender differences observed in all the parameters assayed across all the 
treatment groups hence the presentation of combined (male and female) results.  
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2.6.1 Morbidity and mortality 
 
 All the pups remained healthy throughout the study with no incidental or iatrogenic 
morbidities or mortalities recorded. 
 
2.6.2. Effects of HS aqueous calyx extract on growth performance 
 
2.6.2.1 Body mass 
 
Figure 2.1 shows the effects of orally administered HS aqueous calyx extracts on the terminal 
body masses of the rat pups. The induction and terminal masses of the rats were not 
significantly different (p>0.05) across the treatment groups (Figure 2.1). The pups in all the 
treatment groups however significantly grew (p<0.001) from induction to termination (Figure 
2.1).  
 
Figure 2.2 shows the percentage body mass gain of the rat pups following oral administration 
of HS aqueous calyx extracts. There was no significant difference (p>0.05) in the percentage 
body mass gain of the rat pups during the treatment period.  
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Figure 2.1: Effect of oral administration of aqueous HSE on the terminal body masses of 
rat pups. ***=p<0.001. CTRL= control (10ml.kg
-1
 distilled water), HD HSE= high dose of 
HS extract (500mg.kg
-1
), LD HSE= low dose of HS extract (50mg.kg
-1
). Data presented as 
mean± SD; n=14 in each group. 
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Figure 2.2: Effect of oral administration of HS aqueous calyx extract on Percentage 
change in body mass of pups. CTRL= control (10ml.kg
-1
 distilled water), HD HSE= high 
dose of HS extract (500mg.kg
-1
), LD HSE= low dose of HS extract (50mg.kg
-1
). Data 
presented as mean± SD; n=14 in each group. 
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2.6.2.2 Linear growth 
 
Table 2.1 shows the effect of oral administration of HS aqueous calyx extracts on the masses, 
lengths and densities of tibiae and femora of suckling Sprague Dawley pups. Pups 
administered with the LD HSE had significantly heavier tibiae (p<0.05) compared to those of 
the control and HD HSE (Table 2.1). Pups in the LD HSE had denser tibiae than pups in the 
HD HSE and CTRL groups (Table 2.1). 
 
Table 2.1 Effect of oral administration of HS aqueous calyx extracts on the masses, 
lengths and density of tibiae and femora of suckling Sprague Dawley pups 
 CTRL LD HSE HD HSE 
Tibia (mg) 32± 3.5
a
 34± 3.5
b
 30± 4.6
a
 
Tibia (mm) 16± 1.0
a
 15± 1.2
a
 15± 1.4
a
 
Tibia (mg.mm
-1
) 2.0± 0.2
a
 2.9± 0.3
b
 2.0± 0.2
a
 
Femur (mg) 32± 3.2
a
 32± 3.4
a
 30± 2.8
a
 
Femur (mm) 12± 0.7
a
 12± 0.7
a
 12± 0.4
a
 
Femur (mg.mm
-1
) 2.7± 0.2
a
 2.7± 0.2
a
 2.6± 0.2
a
 
 
ab
Within rows, means with different superscripts are statistically different from each other. 
CTRL= control (10ml.kg
-1
 distilled water), HD HSE= high dose of HS extract (500mg.kg
-1
), 
LD HSE= low dose of HS extract (50mg.kg
-1
). Data expressed as mean± SD, n=14 in each 
group. 
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2.6.3 Hepatic storage of metabolic substrates 
 
Figures 2.3A and 2.3B show hepatic lipid and glycogen content respectively.  There were no 
differences (p>0.05) in the liver lipid (Figure 2.3A) and glycogen content (expressed as 
glucose equivalents in liver hydrosylate) (Figure 2.3B) across the treatment groups. 
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Figure 2.3A: Effect of administration of HS aqueous calyx extracts on liver lipid content 
in suckling Sprague Dawley rat pups 
CTRL= control (10ml.kg
-1
 distilled water), HD HSE= high dose of HS extract (500mg.kg
-1
), 
LD HSE= low dose of HS extract (50mg.kg
-1
). Data expressed as mean± SD, n=14 in each 
group. 
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2.6.3.2 Hepatic glycogen content 
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Figure 2.3B: Effects of administration of HS aqueous calyx extract on the liver glycogen 
stores of suckling Sprague Dawley rats 
CTRL= control (10ml.kg
-1
 distilled water), HD HSE= high dose of HS extract (500mg.kg
-1
), 
LD HSE= low dose of HS extract (50mg.kg
-1
). Data expressed as mean± SD, n=14 in each 
group. 
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2.6.4 Morphology and morphometry of the GIT and other viscera 
 
Table 2.2 shows the effect of administration of HS aqueous calyx extract on the morphometry 
of the GIT and liver of suckling Sprague Dawley pups. The small intestines of the pups 
administered with the HD HSE were significantly heavier relative to the body mass (p<0.05) 
when compared to those on the LD HSE and the CTRL group (p<0.001).  The caeca of pups 
administered with the HD HSE were significantly heavier (absolute and relative to the body 
mass) compared to those on the LD HSE (p<0.05). There were no differences observed 
(p>0.05) in the lengths of the small and large intestines, absolute and relative masses of the 
large intestines, stomach and liver (Table 2.2). 
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Table 2.2: Effect of administration of HS aqueous calyx extract on the morphometry of 
the GIT and liver of suckling Sprague Dawley rats 
 CTRL LD HSE HD HSE 
S.I.(g) 0.71 ± 0.07 0.72 ±0.06 0.77± 0.09 
S.I. (% BM) 2.7 ± 0.30
b
 2.7 ± 0.20
b
 3.0 ± 0.20
a
 
S.I. (mm) 498 ± 27.00 517 ± 43.00 509 ± 30.00 
L.I. (g) 0.10 ± 0.01 0.10 ± 0.01 0.11 ± 0.01 
L.I. (% BM) 0.39 ± 0.05 0.40 ± 0.05 0.42 ± 0.05 
L.I. (mm) 71± 4.80 72 ± 4.70 70 ± 5.30 
Liver (g) 0.80 ± 0.06 0.79 ± 0.07 0.76 ± 0.06 
Liver (%BM) 3.0 ± 0.17 2.9 ± 0.17 3.0 ± 0.14 
Caecum (g) 0.056± 0.01
a
 0.049± 0.01
ac
 0.062± 0.02
ab
 
Caecum(%BM) 0.21± 0.05
a
 0.19± 0.04
ac
 0.24± 0.06
ab
 
Stomach (g) 0.17 ± 0.02 0.16 ± 0.02 0.17 ± 0.02 
Stomach (%BM) 0.63 ± 0.08 0.59 ± 0.07 0.66 ± 0.07 
ab
Within row data with different superscripts indicate significant difference (p <0.05).  S.I. = 
small intestines, L.I. = large intestines, BM = body mass, CTRL= control (10ml.kg
-1
 distilled 
water), HD HSE= high dose of HS extract (500mg.kg
-1
), LD HSE= low dose of HS extract 
(50mg.kg
-1
). Data expressed as mean± SD, n=14 in each group. 
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2.6.5 Biochemical health profile  
 
Table 2.3 shows the effect of administration of HS aqueous calyx extract on the biochemical 
markers of health of suckling Sprague Dawley pups. There was no significant difference 
(P>0.05) in biochemical markers of health measured across the treatment groups (Table 2.3). 
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Table 2.3: Effects of administration of HS aqueous calyx extract on the biochemical 
markers of health of suckling Sprague Dawley rats 
 CTRL LD HSE HD HSE  
Glucose (mmol.L
-1
) 6.4 ± 1.30 6.2 ± 0.94 6.9 ±1.10 
BUN (mmol.L
-1)
 3.8 ± 0.94 3.8 ± 0.67 4.0 ± 1.20 
Creatinine (µmol.L
-1
) 18 ± 6.10 21 ± 12.00 19 ± 9.70 
Phosphate (mmol.L
-1
) 2.9 ± 0.29 2.9 ± 0.21 2.7 ± 0.23 
Calcium (mmol.L
-1
) 2.4 ± 0.53 2.3 ± 0.36 2.5 ± 0.24 
Total  Protein (g.L
-1
) 39 ± 4.80 40 ± 2.80 40 ± 2.90 
Albumin (g.L
-1
) 16 ± 4.70 15 ± 5.90 16 ± 5.60 
Globulin (g.L
-1
) 23 ± 1.10 25 ± 4.90 24 ± 3.40 
ALT (U.L
-1
) 50± 36.00 59 ± 56.00 44 ± 24.00 
ALP (U.L
-1
) 382 ± 67.00 425 ± 76.00 438 ± 65.00 
Total Biluribin (µmol.L
-1
) 10 ± 3.60 10 ± 5.70 9.2 ± 3.40 
Cholesterol (mmol.L
-1
) 4.1 ± 0.32 4.4 ± 0.28 4.4 ± 0.30 
Amylase (U.L
-1
) 1272 ± 254.00 1349 ± 162.00 1347 ± 173.00 
BUN= blood urea nitrogen, CTRL= Control (10ml.kg
-1
), HD HSE= High dose of HS extracts 
(500mg.kg
-1
), LD HSE= Low dose of HS extracts (50mg.kg
-1
), Data expressed as mean± SD, 
n=14 in each group. 
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2.7 Discussion 
 
In this phase of the study, the effects of administration of an aqueous calyx extract of HS on 
the growth performance, metabolic substrates, gastrointestinal tract and general health of 
suckling rat pups was investigated. The findings of this phase will be discussed in the 
subsequent paragraphs. 
 
2.7.1 Effects of HS aqueous calyx extracts on growth performance 
 
The pups in all the treatment groups had similar induction masses and grew significantly 
during the study period.  The effects of sex hormones  that may account for differences in 
growth rates only appear around postnatal day 25-36 in rats  (Eden, 1979; Gabriel et al., 
1992). The pups in this phase of the study were terminated at postnatal day 14 and this might 
explain why gender differences were not observed in the measured parameters. Body mass is 
usually affected by a range of factors such as genetic predisposition, the state of hydration of 
the individual, nutritional status and disease conditions (MacCracken and Stebbings, 2012).  
The morphometric characteristics of the tibiae and femora are more reliable indices of growth 
because they are related to growth hormone and IGF-1 activity in a dose dependent manner 
compared to other tissues (Baum et al., 1996; Eshet et al., 2004). The long bones are also not 
susceptible to daily fluctuations resulting from hydration status or gut fill (Baum et al., 1996).   
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The tibiae of the pups in the low dose HSE group were significantly longer and heavier than 
those of the control and high dose HS groups. The determination of the bone density was done 
indirectly by computation of the lengths and masses of the bones and not through radiographs 
and densitometry. Therefore the higher density of the tibiae might be due to proteins or other 
bone components and not necessarily due to mineralization. Hibiscus sabdariffa calyces have 
about 12.63mg/100g calcium (Mahadevan et al., 2009), which is in addition to the calcium 
content of the dam‘s milk and might contribute to the mineralization of the long bones. 
However, HS calyces were also reported to have a high phosphorus content of about 
273.2mg/100g (Mahadevan et al., 2009) with a calcium/phosphorus ratio of 0.05. 
Calcium/phosphorus ratio range from 1.51 in neonatal to 1.69 in adult rats (Legros et al., 
1987; Nieves, 2005). Excessive intake of phosphorus in relation to calcium has deleterious 
effects on bone mineralization (Nieves, 2005). This might explain why the pups that were 
administered with the high dose HSE had shorter and lighter tibiae than those given the high 
dose of HSE.  
 
2.7.2 Effects of HS on hepatic storage of lipids and glycogen 
 
Dietary interventions  and starvation have been shown to affect the liver storage of lipids and 
glycogen  (Barcellos et al., 2010). The liver is an important organ in the body performing a 
wide range of metabolic, synthetic and storage functions. Hepatic lipids serve as a concentrate 
of large energy stores to be used by the body in times of need (Sugden et al., 2002). Hibiscus 
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sabdariffa extracts have been reported to decrease lipid content of hepatocytes via the 
activation of adenosine monophosphate-activated protein kinase (AMPK) and reduction of 
sterol regulatory element- binding protein 1 (SREBP-1) consequently preventing the 
expression of the enzymes: fatty acid synthase and HMG-CoA reductase (Yang et al., 2009).  
In this study, there was no difference  observed in the hepatic storage of lipids between the 
HSE treated and control groups  suggesting that HSE might not have had an effect on the 
hepatic liver content of the pups. 
 
 Hibiscus sabdariffa has been reported to have hypoglycaemic effects (Peng et al., 2011; 
Adisakwattana et al., 2012; Villalpando-Arteaga et al., 2013a) which should have affected the 
liver glycogen stores. The hypoglycaemic effect should have caused glycogenolysis in the 
liver leading to a reduction in the hepatic glycogen stores. There was no significant difference 
observed in liver glycogen content between the HS treated groups and the control group in 
this study. This lack of difference in the glycogen stores across the treatment groups might be 
because the pups were not fasted prior to termination. Fasting of the pups would have 
required separating them from their dams and since the pups do not all suckle at the same time 
it would be difficult to determine the duration of fasting. 
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2.7.3 Effects of HS on the morphometry of the GIT  
 
The GIT is the most widely exposed system to the effects of phytochemicals and responds to 
this exposure in diverse ways (Buddington and Kimura, 2003). Some vertebrates are able to 
increase the size of their GIT in response to the fibre content of the diet (Sorensen et al., 
2010). Plant extracts have previously been shown to cause precocious maturation of the GIT 
in rats (Linderoth et al., 2005). In this study, HS extracts caused a significant increase 
(p<0.001) in the mass of the small intestines relative to the body mass  in the high dose group 
when compared to the control group and low dose groups (p<0.01). This could probably point 
to trophic effects of high dose HSE on the small intestines in this period of relative plasticity. 
HS extracts might have interfered with the absorption of nutrients in the small intestines 
leading to their accumulation and subsequent increase in the mass of  the intestines (Younes et 
al., 2001; Lembede, 2014).  
The caecum of the rat is the main site of degradation of fermentable carbohydrates and other 
residual nutrients (Munro et al., 1998; Younes et al., 2001). In this study, the absolute (g) and 
relative (%BM) mass of the caecum differed significantly between the high dose HS 
(500mg.kg
-1
) and the low dose HS (50mg.kg
-1
) treatment groups but not with the control 
group. An increase in the caecal mass usually occurs following introduction of a variety of 
substances into the GIT and is thought to result from the osmotic activity of substances not 
absorbed by the small intestines or an alteration of the GIT flora by dietary changes (Ford et 
al., 1983; Munro et al., 1998; Erlwanger and Cooper, 2008). There may be positive or 
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negative associative factors responsible for this observed difference in caecal mass between 
the two different treatment groups (LD HSE and HD HSE) which are both similar to the 
control group. However, full explanation cannot be provided by this study.  
 
 Hibiscus sabdariffa extracts did not have any grossly discernable effects on the remaining 
GIT and non-GIT viscera. 
 
2.7.4 Effect of HS on markers of health 
 
There were no adverse health outcomes observed in the pups following the administration of 
HS aqueous calyx extracts. Even though some researchers have found adverse effects in the 
liver enzymes following chronic administration of high doses of HS (Akindahunsi and 
Olaleye, 2003) others reported HS to be safe (Onyenekwe et al., 1999; Gaya et al., 2009; Ndu 
et al., 2011). Plasma activity of alkaline phosphatase (ALP) though not significantly different 
(p>0.05) was found to be elevated above the upper limit (370U.L
-1
) for adult rats (Espandiari 
et al., 2008) in all the treatment groups. Alkaline phosphatase is a non- specific enzyme 
released from multiple sources which include the intestinal mucosa, osteoblasts and epithelial 
cells of biliary canaliculi (Alhassan et al., 2009). The increased activity of ALP might be due 
to increased osteoblastic activity that accompanies growth (Alhassan et al., 2009)  and not as a 
result of damage to the liver. The particular ALP isozyme that was elevated was not 
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determined in this study due to technical limitations and would have shed more light on the 
cause of the increased plasma activity. Plasma activity of ALT and plasma total biluribin and 
total protein concentration, which are all markers of hepatic damage, were not different across 
the treatment groups. Plasma albumin concentrations were low (reference values given by the 
IDEXX machine) but not significantly different in all the treatment groups. However albumin 
concentrations have been reported to be low from 4 days post partum till about 20 days post 
partum due to protein synthesis limitation in the hepatoblasts (Papworth and Clubb, 1995).    
Blood urea nitrogen (BUN) and creatinine were used as surrogate markers of renal function in 
this study. There were no adverse effects observed in these parameters following 
administration of HS aqueous calyx extracts. This finding is in agreement with those of 
Mohagheghi et al., (2010)  who observed no significant harmful changes in blood urea 
nitrogen (BUN), serum creatinine, sodium and potassium concentrations following 
administration of HS tea twice daily for 2 weeks in patients with essential hypertension. Other 
researchers have also attributed reno-protective effects on the extracts of HS through the 
amelioration of diabetic nephropathy (Lee et al., 2009; Wang et al., 2011). Other markers of 
health assayed in the study were also not adversely affected by the administration of HS. 
These results tend to suggest that HS aqueous calyx extracts could be used in neonates 
without any adverse effects on their health. 
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2.11 Conclusion 
 
In this phase of the study, aqueous HS calyx extract was administered to neonatal rat pups via 
oral gavage to determine its effects on their growth performance, metabolic substrates, 
gastrointestinal tract and general health.  While the extracts had a trophic effect on the small 
intestines and caecum of the rat pups, it had no effect on the other parameters that were 
assayed in the study.  These findings suggest that aqueous HS calyx extracts administered 
during the neonatal period could cause precocious structural maturation of the GIT which 
could affect the metabolism and physiology of the animal without any adverse effects on their 
health.  Further research is needed in order to identify the specific phytochemicals and 
mechanisms of action involved in the causation of precocious maturation of GIT and its 
implications for long term health. 
 
Previous studies in which neonatal rat pups were administered with plant extracts (Erlwanger 
and Cooper, 2008; Beya et al., 2012; Dangarembizi et al., 2014)  had speculated on the 
possible perpetuation of the changes observed in the neonatal phase into adulthood and 
whether they conferred any advantage or otherwise in later life.  
 
The second phase of this study which is described in the next chapter, investigated whether 
the trophic changes observed in the small intestines of the pups translated into any form of 
advantage or not in the response of weanling rats to a second intervention (20% fructose w/v 
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in the drinking water of the weanling rats).  It thus also investigated whether the early 
administration of the HSE had any programming effect on the manifestation of metabolic 
dysfunction in the adolescent stage of the rats. 
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CHAPTER THREE: EFFECTS OF 
EARLYADMINISTRATION OF HS 
AQUEOUS CALYX EXTRACT ON THE 
RESPONSE TO A HIGH FRUCTOSE 
DIET
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3.0 Introduction 
 
In the previous chapter, HS aqueous calyx extracts were administered to suckling Sprague 
Dawley rat pups. As stated earlier, previous interventions in the neonatal rats had looked at 
the acute changes in the GIT morphology, growth performance and general health of the pups   
and speculated that the changes observed might have beneficial effects for the animals later in 
life.  
 
This chapter reports on the second phase of the present study. In addition to the administration 
of the HS aqueous calyx extracts in the suckling period, the rats were subjected to a high 
fructose diet at 20% fructose (w/v) in their drinking water. Unlike glucose which activates 
phospho-fructokinase in the glycolytic pathway, fructose activates fructose-1-phosphatase 
leading to lipogenesis (Basciano et al., 2005). Fructose is also common additive in foods 
(Angelova and Boyadjiev, 2013). The aim was to investigate whether the initial intervention 
with HS had conferred any benefits or predisposition to the development of diet induced 
metabolic dysfunction in the growing period.  
 
3.1 Neonatal programming of metabolic dysfunction 
 
Even though the rising incidence of metabolic syndrome has been blamed on lifestyle and 
dietary factors, the exact mechanisms by which these factors affect the physiological systems 
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that regulate appetite,  body mass and aetiology of metabolic diseases is still poorly 
understood (Moura and Passos, 2005). There is strong evidence that some metabolic disorders 
of adulthood actually are as a result of events that happened in early life (Osmond et al., 1993; 
Hales and Barker, 2001; Gluckman and Hanson, 2004).   
 
An individual‘s growth and development is  normally controlled in a programmed sequence 
dictated by the genome right from conception (Patel and Srinivasan, 2002). However, studies 
have shown that during the early periods of development, there is relative plasticity of the 
tissues and the individual responds to environmental stimuli by adapting to them at the 
cellular level (Patel and Srinivasan, 2002).   
 
Neonatal programming has been defined as ―an epigenetic phenomenon by which nutritional, 
hormonal, physical, psychological and other stressful events acting in a critical period of life 
such as gestation and lactation, modify in a prolonged way certain physiological 
functions‖(Moura and Passos, 2005).   
 
There is abundant evidence  from epidemiological studies linking a nutrient deficient uterine 
environment either due to maternal factors or placental insufficiency to the development of 
cardiovascular and metabolic diseases  (Armitage et al., 2004).  Hales and Barker, (2001) 
stimulated a lot of research in this field when they proposed the ‗foetal origins‘ hypothesis 
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which is now used to describe any situation where an event during development causes a 
permanent physiological response. According to Hales and Barker, (2001)  this foetal origin 
of metabolic diseases leads to the expression of a ‗thrifty phenotype‘ which allows the foetus 
to maximise nutrient uptake and utilization in the nutrient-deficient in utero environment. A 
predictive adaptive advantage is conferred on the foetus that prepares it for similar nutrient 
deficient post natal environment (Armitage et al., 2004; Cottrell and Ozanne, 2008).   
  
However, the availability of plentiful nutrition in the post natal environment which exceeds 
the range of predictive adaptive responses of the neonate will result in an increased risk of 
developing obesity and type two diabetes mellitus (Armitage et al., 2004; Cottrell and 
Ozanne, 2008).  
 
Neonatal programming is an epigenetic phenomenon and occurs at the level of gene 
expression rather than gene sequence (Gallou-Kabani and Junien, 2005). Therefore nutritional 
insults during those critical stages of development could influence how certain genes are 
expressed or silenced (Gallou-Kabani and Junien, 2005)  by interfering with the normal  
epigenetic processes. 
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These detrimental metabolic consequences of programming can be transmitted to subsequent 
generations without necessarily repeating the initial insult (Drake and Walker, 2004)  
probably due to permanent changes in the genome (Gallou-Kabani and Junien, 2005).  
Previously, the thrifty hypothesis was based on the premise that only offsprings with low birth 
weight were at an increased risk of metabolic diseases in their adult life. Considering the rise 
in the incidence of obesity in the developed world where maternal malnutrition or under 
nutrition is rarely obtained, research now focused on the link between maternal over-nutrition 
and deleterious metabolic outcomes in later life (Cottrell and Ozanne, 2008). It has now been 
established that offspring of mothers with over-nutrition or those with gestational diabetes are 
large for age at birth with increased risk of obesity and diabetes later in life (Ehrenberg et al., 
2004). This means that at both extremes of birth weight, there is an increased risk of obesity 
(Parsons et al., 2001).  
 
Animal models of growth restriction or over-nutrition have been used to study the 
mechanisms and outcomes of neonatal programming and have provided valuable information 
(Armitage et al., 2004). The lactation period appears to be the most crucial time in mammals 
for the initiation of metabolic programming (Moura and Passos, 2005). Maternal dietary 
manipulation in the form of caloric or protein restriction during gestation have been 
frequently employed as models of metabolic programming with the effects observed in the 
offsprings (Patel and Srinivasan, 2002; Armitage et al., 2004; Moura and Passos, 2005; 
Cottrell and Ozanne, 2008). Unlike the effect of over nutrition in rat pups which has been 
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studied by reducing litter size (McCance, 1962), the effect of altered nutrition during the 
suckling period has been difficult to study because it would involve feeding the pups with a 
modified formula away from their dams (Patel and Srinivasan, 2002).    
Considering the alarming increase in the incidence of metabolic dysfunction and the fact that 
these impairments can be transmitted across generations, the goal of treatment should be to 
prevent this transmission. There is evidence that metabolic symptoms in those individuals 
with intrauterine growth restriction could be reversed with maternal dietary manipulation 
during lactation (Wyrwoll et al., 2006). Therefore, research in this area needs to be intensified 
with the aim of determining whether these early interventions would confer any advantages 
for long term health (Cottrell and Ozanne, 2008).   
 
The incidence of metabolic syndrome is no longer the exclusive preserve of the adults as there 
is an alarming increase in the prevalence of childhood obesity globally (Stamatakis et al., 
2009).  
 
3.2 Childhood Obesity: prevalence and complications 
 
Insulin resistance and type two diabetes mellitus are rapidly emerging as chronic disorders of 
childhood  associated with an increase in the prevalence of obesity (Kohen-Avramoglu et al., 
2003). There is a change in the prevalence of childhood obesity globally, attaining an 
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epidemic proportion (Ebbeling et al., 2002; Birch and Ventura, 2009; Stamatakis et al., 2009). 
This increase in prevalence is due to an interplay of genetic factors, sedentary life style and 
altered diets (Biro and Wien, 2010). Different epidemiological studies defined childhood 
obesity and over-weight in a different manner, making it difficult to make comparisons 
(Ebbeling et al., 2002).   
 
The worldwide prevalence of childhood obesity which increased from 4.2% in 1990 to 6.7% 
in 2010 is expected to reach 9.1% by 2020 (De Onis et al., 2010). In Africa, the estimated 
prevalence of 8.5% in 2010 is expected to increase to 12.7% by 2020 (De Onis et al., 2010). 
The prevalence of childhood obesity in South Africa was found to be increasing with age, 
reaching 20-25% by late adolescence (Kimani-Murage et al., 2010). In Nigeria, a prevalence 
of 5.2% was reported among pre-school children (Senbanjo and Adejuyigbe, 2007) and 1.8% 
among children attending primary and secondary schools in a semi-urban community (Musa 
et al., 2012).  
There are several complications associated with childhood obesity including hypertension, 
dyslipidaemia, hyperinsulinaemia,  proinflammatory and prothrombotic tendencies (Ford, 
2005). Other complications can be grouped as below: 
 
-psychosocial characterised by poor self esteem, depression and eating disorders (Davison and 
Birch, 2001).  
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-neurological such as pseudo-tumour cerebri (Balcer et al., 1999).  
-pulmonary which include  sleep apnoea, asthma and exercise intolerance (Redline et al., 
1999; Figueroa-Munoz et al., 2001).  
- GIT such as  gall stones and  steatohepatitis (Strauss et al., 2000).  
-renal complications like glomerulosclerosis (Adelman et al., 2001).  
- musculoskeletal such as  slipped capital femoral epiphysis, Blount‘s disease, forearm 
fracture and flat feet (Loder et al., 1993; Dowling et al., 2001).  
-endocrine complications which include, type 2 diabetes, precocious puberty, polycystic 
ovarian disease in girls and hypogonadism in boys (Good et al., 1997; Kaplowitz et al., 2001; 
Ludwig and Ebbeling, 2001).  
- cardiovascular characterized by dyslipidaemia, hypertension, coagulopathy, chronic 
inflammation and endothelial dysfunction (Freedman et al., 1999; Ford, 2005).  
It is clear that the complications of childhood obesity are enormous and therefore there is a 
need to intensify research aimed at finding affordable and readily available remedies.  
Resveratrol (a natural phenolic produced in most plants), has been shown to reduce lipid 
peroxidation and increase sirtuin 1 expression in adult Wistar rats that were programmed by 
maternal protein restriction during lactation (Franco et al., 2010). Perhaps other 
phytochemicals in plants could be used to modify the epigenome in the early critical periods 
and prevent the development of obesity.  
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3.3 Fructose-induced metabolic dysfunction 
The rise in incidence of metabolic syndrome has been linked to changes in dietary habits and 
reduced physical exercise (Armitage et al., 2004). Therefore it is appropriate, when studying 
the pathogenesis of the syndrome to use diet induced animal models for those methods not 
applicable to humans (Angelova and Boyadjiev, 2013). Some of the diet induced models used 
in rats include: ‗high-fat diet, high-carbohydrate diet, combined high-fat high-carbohydrate 
diet, diet with a high content of sodium chloride and fructose, dietary regimens simulating 
dietary habits in people as well as prenatal and perinatal dietary manipulations‘(Angelova and 
Boyadjiev, 2013).  
 
Due to its sweetness and affordability, high fructose corn syrup is found in many processed 
foods (Gajda et al., 2007; Angelova and Boyadjiev, 2013). Studies have shown that a high 
fructose diet in rats resulted in insulin resistance and hypertriglyceridaemia within two weeks 
(Pagliassoti et al., 1996). Different amounts and dietary formulations  for oral intake of 
fructose have been used with different features of metabolic syndrome manifesting (Abdulla 
et al., 2011). Fructose feeding in rats causes increased body mass and reduced glucose 
tolerance (Angelova and Boyadjiev, 2013). This is however dependent on the stage of 
maturity at which fructose is introduced (Abdulla et al., 2011). Younger animals tend to gain 
more  mass than older ones (Huynh et al., 2008). Fructose suppresses leptin thereby inhibiting 
satiety and increasing caloric intake and hence weight gain (Teff et al., 2004).  
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 Hyperinsulinaemia and hepatic insulin resistance in  rats have been reported in fructose 
feeding (Tobey et al., 1982) and in humans (Wei et al., 2007). This insulin resistance in 
fructose-fed rats could be as a result of down regulation of insulin receptors in skeletal 
muscles (Abdulla et al., 2011). In rats, fructose feeding for ten weeks  produced 
hyperinsulinaemia, hypertriglyceridaemia and hyperuricaemia (Nakagawa et al., 2006). In a 
study on the mechanisms of fructose-induced hypertriglyceridaemia, Zavaroni et al., (1982)  
found that fructose acts directly on the liver to increase VLDL-TG secretion, 
hyperinsulinaemia and insulin resistance in a rat model. High carbohydrate diets in the rat 
were observed to stimulate lipogenesis in the liver (Chen et al., 1995; Lee et al., 2008) with 
subsequent production of palmitoyl-CoA thereby increasing the fatty acid composition of 
structural lipids in the liver. This increase in structural lipids has been associated with reduced 
skeletal muscle insulin action  and may be a mechanism of action of hepatic insulin resistance 
(Lee et al., 2008).  
3.4 Materials and methods 
 
3.4.1 Source and preparation of HS Calyces 
 
Dried calyces of HS were sourced and processed as mentioned in Chapter two (2.3.1). 
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3.5 Methods 
 
3.5.1 Study animals 
 
A total of eighty five, 4-day old, suckling Sprague Dawley pups from four dams that were 
sourced from the Central Animal Services, University of the Witwatersrand, were used in this 
phase of the study. 
 
3.5.2 Housing and care of the animals 
 
Dams and their respective litter were housed as described in Chapter two (2.4.3) in the first 
part of the study. In the second part of the study, the dams were returned to stock and the pups 
were housed in individual Perspex cages and the environment controlled as described in 
chapter two (2.4.3). 
 
 
3.5.3 Study design 
 
This phase of the study was done in three stages.  The first stage up to day 14 was as 
described in chapter two (2.4.4). Briefly, the pups were randomly assigned to three treatment 
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groups using a split litter pattern. The first group, the control group (n=27, 12males, 15 
females) received 10ml.kg
-1
 of distilled water. The second group (n=30, 13 males, 17 
females) received 50mg.kg
-1
 of aqueous HS calyx extracts while the third group (n=28, 
11males, 17 females) received 500mg.kg
-1 
of aqueous HS calyx extract. All the treatments in 
this phase were administered via oral gavage for 9 consecutive days as described in chapter 
two (2.4.4). The interventions were stopped at 14 days of age which marked the second stage 
whence the pups continued to nurse with their dams till post natal day 21 when they were 
weaned. The dams were returned to stock and the pups were then housed individually as 
described in the preceding section (3.5.2).  
 
In the third stage of this phase of the study, the pups in each of the three treatment groups 
were further sub-divided into a control group that continued on tap water as their drinking 
water and another that received 20% fructose (w/v) in their drinking tap water. The groups 
were as follows: 
I. DW (distilled water) + TW (tap water) = 10ml.kg-1 of distilled water in the first stage 
and tap water in the second and third stages. 
II. DW + FW (fructose water) = 10ml.kg-1 of distilled water in the first stage, tap water in 
the second stage  and 20% fructose (w/v) in their drinking water in the third stage.  
III. LHS (low dose HS) + TW = 50mg.kg-1 HS aqueous calyx extract in the first stage and 
tap water in the second and third stages. 
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IV. LHS + FW = 50mg.kg-1 HS aqueous calyx extract in the first stage, tap water in the 
second stage  and 20% fructose (w/v) in their drinking water in the third stage.  
V. HHS (high dose HS) + TW = 500mg.kg-1 of HS aqueous calyx extract in the first stage 
and tap water in the second and third stages. 
VI. HHS + FW = 500mg.kg-1 of HS aqueous calyx extract in the first stage, tap water in 
the second stage  and 20% fructose (w/v) in the third stage. 
 
The above treatments were continued for four weeks till post natal day 49, when the 
animals were subjected to an oral glucose tolerance test (OGTT), returned to their 
treatment groups and then terminated two days later. 
 
3.5.4 Body mass measurements 
 
The pups were weighed daily in the first stage with a balance (Snowrex Electronic Scale, 
Clover Scales, Johannesburg) in order to adjust the amount of HSE administered so as to 
maintain a constant  dose and also to monitor their growth performance. The rats were 
weighed twice weekly in the second phase using the same balance to monitor their growth and 
general health. 
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3.5.5 Oral glucose tolerance test (OGTT) 
 
Following four weeks of fructose treatment, the rats were subjected to an overnight fast for 12 
hours (rats in all the treatment groups had access to tap water during this period) and then 
subjected to an oral glucose tolerance test to assess their ability to handle a glucose load. On 
the day of the test, the rats were restrained manually, placed in  perspex rat restrainers and 
allowed to adjust  for an hour (in the week preceding the test, the rats had been  placed in the  
restrainers for two hours daily to habituate them). The fasting blood glucose concentration 
was determined for all the rats (0 minute) before they were orally gavaged with a 50% 
glucose solution (D-(+)-Glucose (Sigma-Aldrich, France) at 0.2ml.100g
-1
 body weight. Serial 
blood glucose concentrations were determined at 15, 30, 60 and 120 minutes (Loxham et al., 
2007)  using a calibrated glucometer (Ascensia Elite
TM
, Bayer Corporation, Mishawaka, 
USA).  The tails of the rats were cleaned with alcohol impregnated swabs and blood obtained 
via a pin prick to the tails. The rats were then placed back into their treatment groups for 48 
hours before study termination. 
 
 
3.6 Terminal procedures 
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3.6.1 Termination 
 
The rats were euthanased on post natal day 51, by anaesthetic overdose using intraperitoneal 
sodium pentobarbitone (Eutha-naze, Bayer, Johannesburg, South Africa) at 200mg.kg
-1 
body 
mass following a 12-hour overnight fast.  
 
3.6.2 Collection of blood, plasma processing and storage 
 
This was done as described in chapter two (2.4.6.2). The modification was that blood was 
collected via cardiac puncture using 20G needles and 10ml syringes ( in place of the 21G 
needles and 5 ml syringes used in phase one) to collect about 8ml of blood. Plasma was 
processed as previously described and transferred into three microtubes (Eppendorf, 
Hamburg, Germany) for each animal. Two of the  microtubes (for each rat) were stored at -
20ºC in a freezer (Bosh, Johannesburg, South Africa) for clinical biochemistry and assay of 
hormones while the third  microtube was stored at -80ºC in a freezer                                     
(SS engineering, Johannesburg, South Africa) until needed for thiobarbituric acid reactive 
substances (TBARS) assay. 
3.6.3 Morphometry of the GIT and other viscera 
 
This was carried out as described in chapter two (2.4.6.3). 
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3.6.4 Determination of indices of linear growth  
 
The morphometric characteristics of the anti-gravity bones were determined as described in 
chapter two (2.4.6.4). 
 
3.6.5 Determination of hepatic storage of metabolic substrates 
 
3.6.5.1 Quantification of hepatic lipid stores 
 
The liver lipid storage was quantified using  the method described by Bligh and Dyer, (1959)  
as was done in chapter two (2.4.6.5.1). About 4-6g of liver sample was used. 
 
 
 
3.6.5.2 Quantification of hepatic glycogen stores 
 
Hepatic glycogen stores were quantified as previously described in chapter two (2.4.6.5.2). 
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3.6.6 Determination of biochemical health markers 
 
Biochemical markers were determined as previously described in chapter two (2.4.6.6).  
Additionally, a drop of the plasma was used to determine the plasma levels of triglycerides 
using a calibrated TG-meter (Accutrend® Plus, Roche, Mannheim, Germany).  
 
3.6.7 Determination of thiobarbituric acid reactive substances in the plasma 
 
Thiobarbituric acid reactive substances in the plasma were determined using a TBARS kit (R 
and D Systems, USA) according to the manufacturer‘s instructions. It is based on the 
principle that lipid peroxidation leads to the formation of lipid peroxides which result in the 
formation of malondialdehyde (MDA).  The MDA reacts in the presence of heat with 
thiobarbituric acid to yield a coloured product that absorbs light which can then be measured 
as TBARS. The samples were thawed and acid treated with TBARS acid reagent to 
precipitate interfering proteins and other substances. The samples were then incubated at 
room temperature for 15 minutes and then centrifuged in an eppendorf centrifuge (Eppendorf, 
Hamburg, Germany) at 12,000 x G for 4 minutes. The supernatant was then removed and 
used for the analysis. The optical density was pre-read at 532nm using a microplate reader 
(Bio-Tek Instruments, Vermont, USA). The samples were then incubated at 48ºC in an oven 
(Labcon, South Africa) for two and half hours and the optical densities were read again. The 
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initial optical densities were then subtracted from the final readings. A standard curve was 
generated from the test standards and used to determine the TBARS concentrations of the test 
samples. 
 
3.6.8 Plasma insulin concentration determination and computation of HOMA-IR index 
 
Plasma insulin concentration was determined using the sandwich enzyme linked 
immunosorbent assay kit (DRG®, Rat Insulin High Range, USA) which uses monoclonal 
antibodies that are specific for rat insulin. Optical densities were read at an absorbance of 
450nm using a microplate reader (Multiskan Ascent, Lab system, model nº 354, Helsinki, 
Finland). The concentration of insulin was determined in relation to a standard curve that was 
generated using the test standards.  
 
The homeostatic model assessment of insulin resistance (HOMA-IR) was computed by using 
the equation  provided  by Matthews et al., (1985) :  
HOMA-IR = [Fasting plasma glucose (mg.dl
-1) × fasting plasma insulin (μU.mL-1)] / 40 
3.6.9 Statistical analysis  
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All data from the study was expressed as mean ± standard deviation. Data was analysed using 
GraphPad Prism version 5 (Graph-pad Software Inc., San Diego, USA). The level of 
significance was set at p≤0.05. With the exception of OGTT, data in this phase was analysed 
using a one way analysis of variance to assess the effects of HS extracts on the parameters 
measured. Data from the OGTT was analysed using the repeated measures analysis of 
variance (ANOVA). This was followed by a Bonferroni post hoc test. 
 
3.7 Results  
3.7.1 Growth performance 
3.7.1.1 Body mass changes 
 
The growth performance of male and female Sprague Dawley rats is presented in Figures 
3.1A and 3.1B. 
The rats in all the treatment groups gained weight significantly in both sexes (p<0.001) 
however there was no significant difference (p>0.05) in the body masses of the rats in the 
different treatment groups at induction, weaning and termination. The male rats gained more 
mass (p<0.001) than the female rats across the treatment groups. 
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Figure 3.1A: Effect of fructose administration on the growth pattern of male 
experimental rats across the treatment groups 
*** =p<0.001. DW + TW= 10ml.kg
-1
 distilled water + tap water in the growing period (n=6),     
DW+ FW= 10ml.kg
-1
 distilled water + 20% fructose (w/v) in the drinking water (n=6), 
LHS + TW= 50mgkg
-1 
HS extract + tap water (n=6), LHS + FW= 50mg.kg
-1
 HS extract + 
20% fructose (w/v) in the drinking water (n=7), HHS + TW= 500mgkg
-1
 HS + tap water 
(n=6), HHS + FW= 500mg.kg
-1
 HS extract + 20% fructose (w/v) in the drinking water (n=5). 
Data expressed as mean ± SD. 
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Figure 3.1B: Effects of fructose administration on the growth pattern of female 
experimental rats across the treatment groups.  
***= p<0.001. DW + TW= 10ml.kg
-1
 distilled water + tap water in the growing period (n= 8),    
DW+ FW= 10ml.kg
-1
 distilled water + 20% fructose (w/v) in the drinking water (n=7), 
LHS + TW= 50mgkg
-1 
HS extract + tap water (n=9), LHS + FW= 50mg.kg
-1
 HS extract + 
20% fructose (w/v) in the drinking water (n=8), HHS + TW= 500mgkg
-1
 HS + tap water 
(n=8), HHS + FW= 500mg.kg
-1
 HS extract + 20% fructose (w/v) in the drinking water (n=9). 
Data expressed as mean ± SD. 
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3.7.1.2 Linear growth 
 
Table 3.1 shows the effect of fructose administration on the masses, lengths and densities of 
tibiae and femora of male and female Sprague Dawley rats. The masses, lengths and densities 
of both the tibiae and femora were similar (p>0.05) in the male rats across the treatment 
groups. Similarly, the masses lengths and densities of the tibiae and femora were not different 
(p>0.05) in the female rats across the treatment groups. The male rats in all the treatment 
groups tended to have heavier and longer tibiae than the corresponding females in the groups, 
though not statistically significant (p>0.05).  With the exception of the HHS + FW group, the 
male rats across the treatment groups had heavier and longer femora than the corresponding 
females in the groups. 
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Table 3.1: Effect of fructose administration on the masses, lengths and densities of tibiae 
and femora of male and female rats  
 
Treatments  
Gender Tibia Femur 
Mass 
(mg) 
Length 
(mm) 
Density 
(mg.mm
-1
) 
Mass 
(mg) 
Length 
(mm) 
Density 
(mg.mm
-1
) 
DW + TW Males 344 ± 34 35 ±1.6 9.9 ± 0.6 375 ± 65 28 ±2.0 13 ± 1.4 
Females 294 ± 29 33 ±1.3 8.9 ± 0.6 369 ± 19 27 ±0.9 14 ± 0.4 
DW + FW Males 327± 39 34± 2.1 9.7± 0.9 380 ± 61 28± 1.5 14± 0.4 
Females 311± 26 33± 1.1 9.6± 0.7 348 ± 37 26± 1.7 13± 0.8 
LHS + TW Males 334± 18 34 ±1.4 9.7± 0.7 390± 21 28± 1.0 14± 0.6 
Females 295 ± 40 33± 1.8 8.9 ± 0.9 357± 29 27± 0.6 13± 0.9 
LHS + FW Males 339 ± 36 34± 1.5 9.9 ± 0.7 370 ± 67 27± 1.7 14± 1.8 
Females 297± 32 32± 1.9 9.3± 0.8 348 ± 47 26± 1.7 13± 1.2 
HHS + TW Males 348± 32 34± 2.3 10.0 ± 1.1 395± 21 29± 0.7 14± 1.8 
Females 297± 30 32 ±1.2 9.2 ± 0.7 365± 13 26± 1.1 14± 0.4 
HHS + FW Males 343 ± 9.5 35± 1.0 9.9 ± 0.5 347± 47 27± 1.7 13± 1.0 
Females 306± 42 33± 2.0 9.3± 0.8 355± 50 27± 1.4 13± 1.4 
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DW + TW= 10ml.kg
-1
 distilled water + tap water, DW+ FW= 10ml.kg
-1
 distilled water + 20% 
fructose (w/v) in the drinking water, LHS + TW= 50mgkg
-1 
HS extract + tap water, LHS + 
FW= 50mg.kg
-1
 HS extract + 20% fructose (w/v) in the drinking water, HHS + TW= 
500mgkg
-1
 HS + tap water, HHS + FW= 500mg.kg
-1
 HS extract + 20% fructose (w/v) in the 
drinking water. Data expressed as mean ± SD. 
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3.7.2 Glucose tolerance 
 
Figure 3.2A and 3.2B show the different blood glucose concentrations of male and female 
Sprague Dawley rats at  0, 15, 30, 60 and 120 minutes following oral gavage of 2g.kg
-1
 of 
glucose solution. Figure 3.3A and 3.3B show the total area under the curve of the oral glucose 
tolerance test in male and female Sprague Dawley rats. 
 
At 15 minutes post gavage, the following trend was observed: blood glucose concentration of 
rats in DW + TW was significantly higher (p<0.01) than that of HHS + TW group while that 
of DW + FW was significantly higher (p<0.01) than that of LHS + TW (Figure 3.2A).  The 
glucose concentration of rats in the LHS + TW was significantly higher than that of HHS + 
TW (p< 001) and HHS + FW (p<0.05) (Figure 3.2A). There was no difference in blood 
glucose concentration (p>0.05) at all the other time intervals across the treatment groups 
(Figure 3.4A). There were no differences in blood glucose concentrations in the female rats 
across the treatment groups at the different time intervals except at 15 minutes when blood 
glucose concentration in the DW + FW was  significantly higher (p<0.01) than that of  HHS 
+ FW group (Figure 3.2B). The total area under the curve of the oral glucose tolerance test 
were not significantly different (p>0.05) across the treatment groups in both male and female 
rats (Figures 3.3A and 3.3B). 
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Figure 3.2A: Effects of fructose administration on glucose tolerance in male rats  
***p=<0.001. Blood glucose concentration in all the treatment groups peaked at 15 minutes 
and returned to the basal concentration by 120 minutes post gavage. Blood glucose 
concentration at 15 minutes in all the groups differed (p<0.001) from the basal concentration 
and from that at 120 minutes (p<0.001). DW + TW= 10ml.kg
-1
 distilled water + tap water in 
the growing period (n=6), DW+ FW= 10ml.kg
-1
 distilled water + 20% fructose (w/v) in the 
drinking water (n=6), LHS + TW= 50mgkg
-1 
HS extract + tap water (n=6), LHS + FW= 
50mg.kg
-1
 HS extract + 20% fructose (w/v) in the drinking water (n=7),                           
HHS + TW= 500mgkg
-1
 HS + tap water (n=6), HHS + FW= 500mg.kg
-1
 HS extract + 20% 
fructose (w/v) in the drinking water (n=5). Data expressed as mean± SD. 
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Figure 3.2B: Effects of fructose administration on glucose tolerance in female rats 
***=p<0.001. Blood glucose concentration of female rats in all the groups peaked at 15 
minutes and returned to basal level by 120 minutes post gavage. Blood glucose concentration 
at 15 minutes in all the groups differed (p<0.001) from the basal concentration and from that 
at 120 minutes (p<0.001). DW + TW= 10ml.kg
-1
 distilled water + tap water in the growing 
period (n= 8),DW+ FW= 10ml.kg
-1
 distilled water + 20% fructose (w/v) in the drinking 
water (n=7), LHS + TW= 50mgkg
-1 
HS extract + tap water (n=9), LHS + FW= 50mg.kg
-1
 HS 
extract + 20% fructose (w/v) in the drinking water (n=8), HHS + TW= 500mg.kg
-1
 HS + tap 
water (n=8), HHS + FW= 500mg.kg
-1
 HS extract + 20% fructose (w/v) in the drinking water 
(n=9). Data expressed as mean ± SD. 
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Figure 3.3A: Effects of fructose administration on the total area under the curve of oral 
glucose tolerance test in male rats 
DW + TW= 10ml.kg
-1
 distilled water + tap water in the growing period (n=6), DW+ FW= 
10ml.kg
-1
 distilled water + 20% fructose (w/v) in the drinking water (n=6), LHS + TW= 
50mgkg
-1 
HS extract + tap water (n=6), LHS + FW= 50mg.kg
-1
 HS extract + 20% fructose 
(w/v) in the drinking water (n=7), HHS + TW= 500mgkg
-1
 HS + tap water (n=6), HHS + 
FW= 500mg.kg
-1
 HS extract + 20% fructose (w/v) in the drinking water (n=5), AUC= area 
under the curve. Data expressed as mean± SD. 
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Figure3.3B: Effect of fructose administration on the total area under the curve of oral 
glucose tolerance test in female rats 
DW + TW= 10ml.kg
-1
 distilled water + tap water in the growing period (n= 8),DW+ FW= 
10ml.kg
-1
 distilled water + 20% fructose (w/v) in the drinking water (n=7), LHS + TW= 
50mgkg
-1 
HS extract + tap water (n=9), LHS + FW= 50mg.kg
-1
 HS extract + 20% fructose 
(w/v) in the drinking water (n=8), HHS + TW= 500mgkg
-1
 HS + tap water (n=8), HHS + 
FW= 500mg.kg
-1
 HS extract + 20% fructose (w/v) in the drinking water (n=9), AUC= area 
under the curve. Data expressed as mean ± SD. 
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3.7.3: Effects of fructose administration on circulating metabolic substrates, TBARS, 
insulin and HOMA-IR 
 
Table 3.2 shows the effect of fructose administration on circulating metabolic substrates, 
TBARS, insulin and HOMA-IR of male and female Sprague Dawley rats. There were no 
statistical differences observed (p>0.05) in the plasma fasting blood glucose concentration 
and triglycerides in rats of both sexes across the treatment groups (Table 3.2). The plasma 
concentration of TBARS, insulin, as well as the HOMA-IR were also similar (p>0.05) across 
the treatment groups (Table 3.2).  
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Table 3.2: Effect of fructose administration on metabolic substrates, TBARS, Insulin 
and HOMA-IR of male and female Sprague Dawley rats 
Treatments Gender TBARS 
(µM) 
TGs 
(mmol.L
-1
) 
FBG 
(mmol.L
-1
) 
Insulin 
µU.ml
-1
 
HOMA- IR 
DW + TW Males 0.16±0.03 2.5± 1.30 5.3± 0.81 15± 6.30 3.6± 1.80 
Females 0.15±0.03 1.6±0.36 4.6± 0.70 11± 7.30 2.3± 1.50 
DW + FW Males 0.15±0.03 2.4± 0.73 5.1± 0.94 11± 4.70 2.6± 1.50 
Females 0.16±0.03 2.3±0.81
β
 4.9± 0.67 17± 7.20 4.0± 1.60 
LHS + TW Males 0.15±0.03 1.8± 0.29 4.8± 1.00 12± 8.40 2.6± 1.80 
Females 0.16±0.03 1.7±0.31 5.0± 0.76 9.4± 4.50 2.2± 1.10 
LHS + FW Males 0.15±0.03 2.2± 0.81 5.1± 0.79 15± 8.00 3.6± 2.10 
Females 0.15±0.03 2.8±0.51 4.7± 0.83 15± 9.20 3.3± 2.30 
HHS +TW Males 0.15±0.03 2.0± 0.60 5.2± 0.91 13± 7.10 2.9± 1.70 
Females 0.15±0.03 1.8±0.49 4.8± 0.60 12± 4.50 2.5± 1.00 
HHS + FW Males 0.15±0.03 2.4± 0.41 5.0± 1.00 11± 5.20 2.5± 1.30 
Females 0.16±0.03 2.0±0.50 4.8± 0.79 13± 8.30 2.9± 2.00 
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β
 = significantly different from the corresponding males in the group.                          
TBARS= Thiobarbituric reactive substances, TGs= Triglycerides, FBG= Fasting blood 
glucose,  HOMA-IR= Homeostatic model of Insulin resistance,  DW + TW= 10ml.kg
-1
 
distilled water + tap water,    DW+ FW= 10ml.kg
-1
 distilled water + 20% fructose (w/v) in the 
drinking water, LHS + TW=  50mgkg
-1 
HS extract + tap water, LHS + FW= 50mg.kg
-1
 HS 
extract + 20% fructose (w/v) in the drinking water, HHS + TW= 500mgkg
-1
 HS + tap water, 
HHS + FW= 500mg.kg
-1
 HS extract + 20% fructose (w/v) in the drinking water.  Data 
expressed as mean ± SD.
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3.7.4 Hepatic storage of metabolic substrates 
 
Table 3.3 shows the liver lipids and glycogen content in male and female rats. There was no 
significant difference (p>0.05) in the liver lipid and glycogen content across the treatment 
groups (Table 3.3). No gender differences were also observed (Table 3.3). 
Table 3.3: Liver lipids and glycogen (expressed as glucose equivalents) in male and 
female rats. 
Treatment  Gender Liver lipids 
 (% liver mass) 
Liver glycogen        
( mmol.L
-1
) 
DW + TW Male 2.8 ± 1.00 2.6 ± 0.86 
Females 2.9 ± 1.10 2.0 ± 0.57 
DW + FW Males 3.9 ± 0.85 2.3 ± 1.00 
Females 4.4 ± 1.30 1.4 ± 0.87 
LHS + TW Males 3.2 ± 1.00 2.1 ± 0.28 
Females 4.1 ± 0.93 1.8 ± 0.66 
LHS + FW Males 3.3 ± 0.74 2.4 ± 0.69 
Females 3.5 ± 0.54 1.4 ± 0.87 
HHS + TW Males 3.4± 0.90 2.2 ± 0.46 
Females 3.7 ± 0.48 1.8 ± 0.99 
HHS + FW Males 3.8 ± 0.93 2.0 ± 1.10 
Females 3.8 ± 0.52 1.8 ± 0.69 
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DW + TW= 10ml.kg
-1
 distilled water + tap water,    DW+ FW= 10ml.kg
-1
 distilled water + 
20% fructose (w/v) in the drinking water, LHS + TW=  50mgkg
-1 
HS extract + tap water, LHS 
+ FW= 50mg.kg
-1
 HS extract + 20% fructose (w/v) in the drinking water, HHS + TW= 
500mgkg
-1
 HS + tap water, HHS + FW= 500mg.kg
-1
 HS extract + 20% fructose (w/v) in the 
drinking water. Data expressed as mean ± SD. 
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3.7.5 Morphology of the GIT and other viscera 
 
Table 3.4 shows the effect of fructose administration on the absolute (g), relative masses 
(%BM) and lengths of small and large intestines of male and female rats.  Table 3.5 shows the 
effects of fructose administration on the absolute (g) and relative (%BM) masses of some 
abdominal viscera of male and female rats. The absolute mass of the caeca of male rats in the 
LHS + TW was only significantly greater (p<0.01) than those of HHS + FW group (Table 
3.4). However, when compared relative to the body mass, the caeca of the male rats in the 
LHS +TW were significantly greater than those of their male counterparts in DW + FW 
(p<0.05), LHS + FW (p<0.05) and HHS + FW (p< 0.05) treatment groups (Table 3.5).  
The male rats had significantly heavier (absolute) small intestines (Table 3.4) and liver (Table 
3.5) when compared to the corresponding females in all the treatment groups.  The only 
gender difference observed was in the absolute masses of the large intestines (Table 3.4) in 
the DW + TW group (p<0.01) where those of the male rats were significantly heavier. The 
absolute masses of the stomach were heavier in the male rats (Table 3.5) than the 
corresponding females in the DW + TW (p<0.01) and the HHS + FW (p<0.05) groups. In the 
absolute masses of the caecum (Table 3.5), gender differences were observed in the LHS + 
TW (p<0.001) and HHS + TW (P<0.01) groups with those of the male rats being heavier. 
There was no significant difference (p>0.05) in the masses of the GIT and other viscera 
relative to the terminal body masses (%BM) (Tables 3.4 and 3.5) except for the visceral fat 
where the female rats in the HHS + TW (p<0.01) and HHS + FW (p<0.01) groups had 
significantly higher amounts of visceral fat than their corresponding male counterparts. The 
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male rats in the DW + TW (p<0.05), DW + FW (p<0.05) and LHS + TW (p<0.001) treatment 
groups (Table 3.4) had significantly longer small intestines than their female counterparts. 
There were no differences observed in the lengths of large intestines in the rats (Table 3.4) 
across the treatment groups (P>0.05).
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   Table 3.4 Effect of fructose administration on the absolute (g), relative masses (%BM) and lengths of the small and 
large intestines of male and female rats 
 
 Gender S.I (g) S.I (%BM) S.I (mm) L.I (g) L.I (%BM) L.I (mm) 
DW + TW Males 7.9 ± 1.10 3.2 ± 0.31 1393 ±78.00 1.9 ± 0.28 0.75 ± 0.07 230 ± 21.00 
Females 6.1 ± 0.59
β
 3.3 ± 0.39 1253 ±47.00
β
 1.5 ± 0.08
β
 0.80 ± 0.05 203 ± 15.00 
DW + FW Males 8.1 ± 0.67 3.4 ± 0.33 1392 ± 64.00 1.7 ± 0.20 0.72 ± 0.09 214 ± 4.90 
Females 6.2 ± 0.31
β
 3.3 ± 0.20 1249 ±48.00
β
 1.4 ± 0.15 0.76 ± 0.08 199 ± 14.00 
LHS + TW Males 8.0 ± 0.96 3.3 ± 0.21 1433 ± 82.00 1.7± 0.17 0.73 ± 0.05 227 ± 12.00 
Females 6.3 ± 0.54
β
 3.4 ± 0.28 1252 ±97.00
β
 1.5 ± 0.19 0.82 ± 0.05 211 ± 15.00 
LHS + FW Males 7.9 ± 0.83 3.4 ± 0.35 1379 ± 51.00 1.7± 0.23 0.74 ± 0.05 222 ± 18.00 
Females 6.4 ± 0.30
β
 3.5 ± 0.12 1298 ± 58.00 1.4 ± 0.11 0.77 ± 0.06 210 ± 8.00 
HHS + TW Males 7.8 ± 0.61 3.3 ± 0.20 1379 ± 51.00 1.7 ± 0.11 0.72 ± 0.04 224 ± 9.20 
Females 6.4 ± 0.59
β
 3.4 ± 0.20 1275 ± 81.00 1.6 ± 0.24 0.81 ± 0.08 204 ± 15.00 
HHS + FW Males 7.8 ± 0.72 3.3 ± 0.41 1346 ± 24.00 1.7 ± 0.18 0.72 ± 0.06 220 ± 26.00 
Females 6.1 ± 0.44
β
 3.3 ± 0.16 1247 ± 38.00 1.4 ± 0.10 0.74 ± 0.09 199 ± 15.00 
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β 
= significantly different from the corresponding males in the group. S.I= small intestines, 
L.I= large intestines, BM= body mass, DW + TW= 10ml.kg
-1
 distilled water + tap water,  
DW+ FW= 10ml.kg
-1
 distilled water + 20% fructose (w/v) in the drinking water, LHS + TW=  
50mgkg
-1 
HS extract + tap water, LHS + FW= 50mg.kg
-1
 HS extract + 20% fructose (w/v) in 
the drinking water, HHS + TW= 500mgkg
-1
 HS + tap water, HHS + FW= 500mg.kg
-1
 HS 
extract + 20% fructose (w/v) in the drinking water. Data expressed as mean ± SD
  
107 
 
Table 3.5: Effect of fructose administration on the absolute (g) and relative (%BM) masses of some abdominal viscera 
of male and female rats 
Treatments Gender Liver (g) Liver 
(%BM) 
Stomach 
(g) 
Stomach 
(%BM) 
Caecum 
(g) 
Caecum 
(%BM) 
Visceral 
fat (g) 
Visceral 
fat(%BM) 
DW + TW Males 10± 1.40 4.0± 0.25 1.6± 0.18 0.64±0.06 1.3±0.18
ab
 0.51±0.06
ab
 2.9 ± 0.81 1.2 ± 0.24 
Females 7.0±0.38
β
 3.8± 0.20 1.3±0.11
β
 0.68±0.06 1.0±0.10
ab
 0.55±0.05
ab
 3.4 ± 0.73 1.9 ± 0.42 
DW + FW Males 9.9± 1.10 4.2± 0.27 1.6± 0.12 0.67±0.04 1.1±0.21
ab
 0.48±0.08
b
 3.9 ± 1.20 1.6 ± 0.35 
Females 7.5± 0.44
β
 4.0± 0.28 1.3± 0.11 0.72±0.06 0.9±0.10
ab
 0.49±0.06
ab
 4.3 ± 0.81 2.3 ± 0.42 
LHS + TW Males 9.5± 1.70 4.0± 0.55 1.5± 0.17 0.63±0.05 1.5±0.18
b
 0.62±0.07
a
 3.0 ± 0.81 1.3 ± 0.32 
Females 7.4± 0.89
β
 4.0± 0.34 1.4 ± 0.16 0.74±0.08 1.0±0.14
abβ
 0.53±0.07
ab
 3.7 ± 0.99 2.0 ± 0.47 
LHS + FW Males 9.4± 0.83 4.0± 0.26 1.6± 0.14 0.67±0.05 1.2±0.17
ab
 0.49±0.04
b
 3.4 ± 0.72 1.4 ± 0.25 
Females 7.2± 0.54
β
 3.9± 0.31 1.4± 0.08 0.73±0.02 1.0±0.14
ab
 0.52±0.07
ab
 4.1 ± 1.10 2.2 ± 0.55 
HHS + TW Males 9.5± 0.61 4.0± 0.22 1.6± 0.14 0.66±0.07 1.4±0.17
ab
 0.57±0.07
ab
 2.7 ± 0.40 1.1 ± 0.13 
Females 7.3± 1.00
β
 3.9± 0.35 1.3± 0.18 0.71±0.06 1.0±0.21
abβ
 0.55±0.08
ab
 3.9 ± 0.92 2.1 ± 0.43
β
 
HHS + FW Males 9.7± 0.89 4.1 ±0.31 1.6± 0.17 0.69±0.10 1.1±0.13
a
 0.47±0.07
b
 3.4 ± 0.54 1.4 ± 0.23 
Females 7.5± 0.87
β
 4.0± 0.21 1.3±0.11
β
 0.71±0.04 0.9±0.11
ab
 0.48±0.07
ab
 4.7 ± 1.70 2.5 ± 0.77
β
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ab 
within columns means with different superscripts are significantly different at p ≤0.05.         
β 
= significantly different from the corresponding males in the group. DW + TW= 10ml.kg
-1
 
distilled water + tap water,    DW+ FW= 10ml.kg
-1
 distilled water + 20% fructose (w/v) in the 
drinking water, LHS + TW=  50mgkg
-1 
HS extract + tap water, LHS + FW= 50mg.kg
-1
 HS 
extract + 20% fructose (w/v) in the drinking water, HHS + TW= 500mgkg
-1
 HS + tap water, 
HHS + FW= 500mg.kg
-1
 HS extract + 20% fructose (w/v) in the drinking water. Data 
expressed as mean ± SD. 
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3.7.6 Markers of hepatic and renal health 
 
Table 3.6 shows the effect of fructose administration on surrogate markers of renal and 
hepatic health in male and female Sprague Dawley rats. The concentration of alanine 
transaminase (ALT) in the male rats in the DW + FW was significantly higher (p<0.01) than 
their male counterparts in the HHS + TW (Table 3.6). The plasma concentration of ALT was 
significantly higher in the male rats than their corresponding females in the HHS + TW 
(p<0.05) treatment groups (Table 3.6). Similarly, the plasma concentrations of alkaline 
phosphatase (ALP) was higher in the male rats in the DW + TW (p<0.01), LHS + FW 
(p<0.01), HHS + TW (p<0.05) and HHS + FW (p<0.05) treatment groups than the 
corresponding females in the groups (Table 3.6).  
There was no significant difference observed in the plasma concentration of total biluribin, 
creatinine and blood urea nitrogen (p>0.05) across the treatment groups (Table 3.6). 
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Table 3.6: Effect of fructose administration on surrogate markers of hepatic and renal 
health in male and female Sprague Dawley rats 
Treatments  Gender ALT 
(U.L
-1
) 
ALP 
(U.L
-1
) 
Tbil 
(µmol.L
-1
) 
 
BUN 
(mmol.L
-1
) 
Creat 
(mmol.L
-1
) 
DW + TW Males 87±19.00
ab
 380± 61 2.0± 0.00 5.5± 1.40 28± 3.30 
Females 85±20.00
ab
 243±32
β
 2.6± 1.10 4.3± 1.20 29± 5.90 
DW + FW Males 67±16.00
a
 335± 47 2.2± 0.41 4.5± 1.40 28± 6.30 
Females 74± 14.00
ab
 253± 58 3.1± 2.60 4.6± 1.10 34± 5.80 
LHS + TW Males 98± 23.00
ab
 356± 45 2.0± 0.00 4.8± 1.90 24± 4.60 
Females 91± 18.00
ab
 273± 82 2.1± 0.33 5.6± 0.99 30± 9.60 
LHS + FW Males 78± 13.00
ab
 366± 75 2.1± 0.38 5.0± 0.40 29± 6.40 
Females 69± 12.00
ab
 229±41
β
 2.1± 0.35 5.3± 1.00 30± 4.10 
HHS +TW Males 107±28.00
b
 374± 87 3.5± 2.70 6.1± 1.50 27± 7.60 
Females 74± 6.10
abβ
 252±47
β
 2.0± 0.00 5.4± 0.79 31± 7.90 
HHS + FW Males 78± 15.00
ab
 359± 61 2.6± 1.30 5.0± 1.20 28± 7.10 
Females 70± 10.00
ab
 241±53
β
 2.0± 0.00 4.4± 0.81 29± 5.60 
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Means with different superscripts in a column are significantly different (p ≤0.05),                     
β 
= significantly different from the corresponding males in the groups. ALT= Alanine 
transaminase, ALP= Alkaline phosphatase, BUN= Blood Urea Nitrogen,  Tbil= Total 
Biluribin, Creat= Creatinine , DW + TW= 10ml.kg
-1
 distilled water + tap water,    DW+ FW= 
10ml.kg
-1
 distilled water + 20% fructose (w/v) in the drinking water, LHS + TW=  50mgkg
-1 
HS extract + tap water, LHS + FW= 50mg.kg
-1
 HS extract + 20% fructose (w/v) in the 
drinking water, HHS + TW= 500mgkg
-1
 HS + tap water, HHS + FW= 500mg.kg
-1
 HS extract 
+ 20% fructose (w/v) in the drinking water. Data expressed as means ± SD. 
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3.7.7 Markers of general health 
Table 3.7 shows the effect of fructose administration on the general health markers in the 
plasma of male and female Sprague Dawley rats. There was no significant difference (p>0.05) 
in all the general health markers assayed between the male rats in all the treatment groups. 
There was also no significant difference (p>0.05) observed between the female rats across the 
treatment groups in all the general health markers assayed. The plasma concentration of 
calcium was significantly higher in male rats than their corresponding females (p<0.05) in the 
LHS + FW (p<0.05) treatment group (Table 3.7).  Plasma concentrations of amylase was 
higher in the male rats compared to the corresponding females in the DW + TW (p<0.001), 
LHS + TW (p<0.05), LHS + TW (p<0.05), LHS + FW (p<0.001) and HHS + FW (p<0.05) 
treatment groups (Table 3.7).  However, the plasma concentration of cholesterol was higher in 
the female rats compared to the male rats in the HHS + FW (p<0.05) group. There were no 
significant differences (p>0.05) in the other health markers measured across all the treatment 
groups (Table 3.7). 
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Table 3.7: Effect of fructose administration on the general health markers in the plasma of male and female Sprague 
Dawley rats 
 
 
Treatments  Gender Phosphate 
(mmol.L
-1
) 
Calcium 
(mmol.L
-1
) 
Total 
protein 
(g.L
-1
) 
Albumin 
(g.L
-1
) 
Globulin 
(g.L
-1
) 
Amylase 
(U.L
-1
) 
Cholesterol 
(mmol.L
-1
)  
DW + TW Males 2.6± 0.37 2.9± 0.17 55± 2.90 28± 2.10 27± 1.20 1833± 211 1.8± 0.21 
Females 2.2± 0.53 2.8± 0.04 54± 2.30 28± 1.30 26± 0.89 1147± 244
β
 1.9± 0.25 
DW + FW Males 2.4± 0.27 2.8± 0.05 56± 1.90 29± 1.30 27± 1.50 1950±123 2.1± 0.12 
Females 2.5± 0.20 2.8± 0.04 55± 2.30 29± 2.40 25± 1.50 1552±418 2.2± 0.19 
LHS + TW Males 2.7± 0.29 2.8± 0.08 54± 2.30 27± 0.98 26± 1.80 1746±86 1.7± 0.08 
Females 2.4± 0.31 2.8± 0.08 55± 3.40 30± 2.50 25± 2.40 1263±259
β
 2.0± 0.20 
LHS + FW Males 2.7± 0.41 3.0± 0.04 54± 1.90 29± 1.90 25± 1.10 1997± 254 1.9± 0.31 
Females 2.3± 0.24 2.8± 0.05
β
 55± 2.00 29± 1.90 26± 1.30 1375± 207
β
 2.2± 0.42 
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Table 3.7: continued 
 
 
HHS + TW Males 2.5± 0.35 2.8± 0.06 55± 2.20 29± 1.70 26± 1.20 1735± 201 1.8± 0.14 
Females 2.2± 0.16 2.8± 0.06 56± 1.80 29± 1.20 27± 1.10 1295±2241 2.2± 0.27 
HHS + FW Males 2.7± 0.28 2.9± 0.10 54± 3.10 29± 2.40 25± 1.10 2084± 218 1.7± 0.18 
Females 2.2± 0.38 2.8± 0.07 55± 1.40  29± 1.20 26± 0.88 1540± 303
β
 2.2± 0.34
β
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 β 
= significantly different from the corresponding males in the groups. DW + TW= 10ml.kg
-1
 
distilled water + tap water,    DW+ FW= 10ml.kg
-1
 distilled water + 20% fructose (w/v) in 
the drinking water, LHS + TW=  50mgkg
-1 
HS extract + tap water, LHS + FW= 50mg.kg
-1
 
HS extract + 20% fructose (w/v) in the drinking water, HHS + TW= 500mgkg
-1
 HS + tap 
water, HHS + FW= 500mg.kg
-1
 HS extract + 20% fructose (w/v) in the drinking water. Data 
expressed as means ± SD. 
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3.8 Discussion 
 
In this phase of the study, the rat pups were initially administered with HS extracts and then at 
weaning were given 20% fructose (w/v) in their drinking water to investigate whether the 
earlier administration of HS had any effect on their response to an insult by a high fructose 
diet. The discussion will focus on the observed differences in response to fructose challenge 
among the treatment groups taking into consideration any gender differences that may have 
occurred. 
 
3.8.1 Growth performance of male and female rats 
 
Sex differences in rates of growth of  rats usually begin to manifest between post natal day 25 
to 33 in favour of the males and are usually preceded by an increase in testosterone levels 
(Eden, 1979; Gabriel et al., 1992). This could explain why the males in all the experimental 
groups in this study gained more weight than their corresponding female counterparts.  
As discussed in chapter two, body mass is usually affected by a number of factors such as 
hydration status and GIT filling (Ellis et al., 2002; MacCracken and Stebbings, 2012) and may 
therefore not be the best indicator of growth performance. The lengths  of the long bones are 
better markers of growth as they correlate with growth hormone secretion in a dose-dependent 
manner (Baum et al., 1996; Eshet et al., 2004). In this study, there was no significant 
difference in the lengths, masses and densities of the tibiae and femora across the different 
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groups although the male rats had longer and heavier tibiae when compared to their 
corresponding females. With the exception of the HHS + FW group, the male rats in all the 
other groups also had longer and heavier femora than the corresponding females in the 
groups. These findings tend to suggest that neither the earlier administration of HS extracts 
nor that of 20% fructose had any effect on the growth performance of the male and female 
rats. 
 
3.8.2 Glucose tolerance, fasting blood glucose, Insulin and HOMA-IR  
 
Fructose administration in rats is known to produce features of metabolic syndrome including 
impaired glucose tolerance. It has previously been shown that 20% fructose in drinking water 
for 5 weeks (Ramadan et al., 2012) and 8 weeks (Mamikutty et al., 2014) is sufficient to cause 
metabolic derangements in Wistar Albino rats. When 25% fructose was used in the drinking 
water, there was a reduction in fluid intake of the rats probably due the increased sweetness of 
the fluid (Mamikutty et al., 2014). Hence, 20% fructose in drinking water was used. In this 
study, both males and female rats in all the treatment groups showed normal ability to handle 
an oral glucose load (Figures 3.3A and 3.3B). The blood glucose concentrations peaked at 15 
minutes following the administration of the glucose load and returned to basal levels by 120 
minutes post gavage. The differences observed in blood glucose concentration at 15 minutes 
post gavage across the treatment groups, especially in the male rats may indicate early 
manifestation of glucose handling problems. However, further analysis with area under the 
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curve of the OGTT revealed no differences. In this study, there was no significant difference 
in the fasting blood glucose, insulin concentration and the computed HOMA-IR across the 
treatment groups. The fasting plasma triglycerides concentrations were also not significantly 
different except between the males and females in the low dose HSE + FW group .This 
similarity in the glucose tolerance, fasting plasma glucose, fasting triglycerides, cholesterol, 
insulin and the HOMA-IR suggests that the administration of 20% fructose (w/v) in drinking 
water of the rats did not induce metabolic dysfunction.  Fructose administration  is known to 
cause reduced glucose tolerance  and  body mass gain (Angelova and Boyadjiev, 2013), 
hyperinsulinaemia and insulin resistance in rats (Tobey et al., 1982). Fructose feeding for ten 
weeks in adolescent rats (150-200g) had previously been shown to produce 
hyperinsulinaemia, hypertriglyceridaemia and hyperuricaemia (Nakagawa et al., 2006). The 
findings in this study were also at variance with those of Pagliassoti et al., (1996)  that 
fructose feeding for two weeks is enough to produce hypertriglyceridaemia and insulin 
resistance. With the exception of the triglycerides where there was a gender difference in the 
LHS + FW group, there was no gender difference in the response of the rats to fructose 
administration for glucose handling, fasting plasma glucose, insulin and HOMA-IR. The age 
of the rats at termination (51 days) and the mode of fructose administration could have been 
factors responsible for the absence of markers of metabolic syndrome. Wistar rats between the 
ages of 2 to 6 months were found to have lower levels of serum glucose, TGs, total 
cholesterol, HDL and LDL when compared to their 12 month old counterparts (Ghezzi et al., 
2012). High fructose intake has been shown to be more effective in inducing metabolic 
syndrome in adults than in young rats (de Moura et al., 2009). Fructose in the feed rather than 
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in drinking water  is also a more effective means of producing metabolic syndrome (de Moura 
et al., 2009) probably because the rats would eat more food (and hence more fructose) than 
water . Unfortunately, even though the rats drank the fructose water, I was unable to take 
record of their actual fluid (fructose) intake in this study. 
3.8.3 Lipid peroxidation 
 
Fructose feeding in rats  activates stress pathways especially in the liver due to burden of 
fructose metabolism (Kelley et al., 2004). High fructose feeding produces 
hypertriglyceridemia, increased serum glucose and total cholesterol which increase lipid 
peroxidation due to the altered lipid metabolism and consequent increase in tissue and plasma 
lipid peroxides (Anurag and Anuradha, 2002; Kelley et al., 2004). Insulin resistance and 
hyperinsulineamia have been associated with increased plasma lipid peroxide levels in 
patients with impaired glucose tolerance (Niskanen et al., 1995)  and with the stress pathway 
(Kelley et al., 2004). Hibiscus sabdariffa has an abundance of antioxidants (Farombi and 
Fakoya, 2005; Usoh et al., 2005; Hirunpanich et al., 2006)  which have been found to 
decrease the increased levels of TBARS usually associated with high fructose feeding 
(Miatello et al., 2005). In this study, the TBARS assay was used to determine lipid 
peroxidation in the plasma as a measure of oxidative damage. The TBARS values obtained   
showed no significant difference across all the treatment groups. This is probably due to non-
development of the symptoms of metabolic syndrome which would have triggered the 
peroxidative damage. However, from the available data in this study, the earlier 
administration of HS in the neonatal period had no effect on the TBARS measured. 
  
120 
 
3.8.4 Hepatic metabolic substrates storage 
 
The liver is a key organ in the body performing numerous functions that maintain 
homeostasis(Michalopoulos, 2007). These functions include maintaining circulating 
metabolic substrates, detoxification, hormone inactivation and storage functions among many 
others (Sawchenko and Mark, 1979; Sallie et al., 1991; Michalopoulos, 2007; Seyama and 
Kokudo, 2009). High fructose feeding causes disturbances in carbohydrate and lipid 
metabolism, consequently affecting the homeostatic functions of the liver (Kelley et al., 
2004). Conventional drugs and plant extracts are partly metabolised in the liver and can also 
alter the functions of the liver. Measurement of surrogate markers of liver function is 
therefore quite important. 
 
High fructose diet causes hypertriglycerideamia which provide substrates for hepatic 
lipogenesis, lipid overload and insulin resistance (Stanhope and Havel, 2008). A 7 day 
administration of a high fructose diet increased ectopic lipid deposition in the liver and 
muscles of healthy non-smoking males  (Lê et al., 2009).  
 
High fructose diet causes an increase in hepatic glycogen stores due to increased conversion 
of fructose to glycogen via gluconeogenesis (Conlee et al., 1987; Koo et al., 2008). Rats fed 
63% fructose (w/w) 4 hours per day for 2 weeks showed increased hepatic glycogen stores 
(Koo et al., 2008).  
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In this study, there was no significant difference (p>0.05) in both hepatic lipids and glycogen 
content across all the treatment groups when compared to the control group. This similarity in 
hepatic lipid and glycogen content could be due to the fact that the animals were fasted 
overnight prior to their termination and sample collection.  
 
3.8.5 The GIT and other viscera 
 
Measurement  of organ masses is very important in toxicological studies as it helps in 
identifying effects of xenobiotics on specific organs (Baltrop and Brueton, 1990; Bailey et al., 
2004). The absolute mass of any organ correlates with the body mass of the animal  (Bailey et 
al., 2004). Relative mass which compare the ratio of the organ mass to the body mass are 
better for comparisons of organ masses in different treatment groups because they account for 
the differences in body mass (Bailey et al., 2004). As described earlier, the terminal masses of 
the male rats differed significantly with those of the corresponding females across all the 
treatment groups. It is therefore understandable that the absolute masses of the organs differed 
between male and female rats in the treatment groups. The absolute masses of the small 
intestines and liver differed between the male and female rats in all the treatment groups. 
However, the absolute masses of some organs such as the large intestines, stomach and 
caecum differed in some but not all the groups. 
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Except in the visceral fat pad where the female rats in the HHS+ TW (p<0.01) and HHS+ FW 
(p<0.01) had significantly greater visceral fat pad than their corresponding male rats, the 
relative masses of all the organs weighed were similar.  Hibiscus sabdariffa aqueous extracts 
were shown to increase body mass index and delay onset of puberty in female rats when 
consumed in the post weaning period (Iyare and Adegoke, 2008). Even though the authors 
also speculated that HS may predispose the female rats to the development of obesity, they 
did not quantify the visceral fats of the animals.  The increased mass of the visceral fat pad in 
the female rats that received high dose of HS in the pre-weaning period needs to be further 
investigated to establish the long term consequences. Hence, neither the administration of HS 
in the neonatal period nor the subsequent fructose feeding might have had a long term effect 
on the morphology of the GIT and non-GIT viscera. 
 
3.8.6 Markers of renal and hepatic health 
 
The glomerular filtration rate is the gold standard for determining renal function but because 
it is difficult to measure clinically, it is usually estimated from serum creatinine 
concentrations (Levey et al., 2009). Serum creatinine and urea concentrations are usually 
elevated in renal disease (Brigden et al., 1982; Haase-Fielitz et al., 2009). In this study, 
plasma creatinine and BUN were used as surrogate markers of renal health. Renal diseases are 
increasingly associated with metabolic syndrome (Wahba and Mak, 2007). Feeding of 60% 
fructose (w/w) for 6 weeks pre- and 11 weeks post-nephrectomy to male Sprague Dawley rats 
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accelerated the progression of chronic kidney disease in the remnant kidney (Gersch et al., 
2007). There were no differences (p>0.05) observed between the treatment groups in both 
plasma creatinine and BUN. It is probably safe to say that the administration of high fructose 
did not result in adverse effects in the kidneys. Because there were no differences observed 
even in the control group (DW + FW), it is difficult to conclude that HS aqueous extracts 
were responsible for preventing the adverse effects of fructose administration in the kidneys. 
 
Alanine transaminase (ALT) is present within the cytosol of the hepatocytes and its elevation 
in the plasma is specifically indicative of damage to the hepatocytes (Thapa and Walia, 2007; 
Thulin et al., 2008; Rajesh et al., 2009). Alkaline phosphatase (ALP) on the other hand, arises 
from multiple sources and elevation of its levels could be as a result of liver damage, 
osteoblastic, placental, intestinal or tumour sources (Pratt and Kaplan, 2000; Thulin et al., 
2008). It is therefore not very specific to the liver. A rise in total plasma biluribin is indicative 
of decreased hepatic clearance or haemolysis (Pratt and Kaplan, 2000; Thapa and Walia, 
2007). Albumin, an important plasma protein is produced by the liver and its level in the 
plasma is a reflection of the synthetic functions of the liver (Alhassan et al., 2009). Plasma 
albumin, total biluribin and total proteins are a measure of hepato-synthetic functions (Thapa 
and Walia, 2007). The plasma concentration of ALT, ALP and total biluribin were used as 
surrogate markers of liver health in this study. 
 
High fructose diet has been shown to cause non-alcoholic liver diseases in rats and this has 
been associated with an increase in the levels of ALT (de Castro et al., 2013). There was no 
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significant difference (p>0.05) in the plasma levels of ALT, ALP and total bilirubin across the 
treatment groups. Gender differences were however found in the level of ALT between the 
males and corresponding females in the HHS + TW (500mg.kg
-1
 HS + tap water) group 
(p<0.05). There was also a significant difference (p<0.01)  between the male rats in DW + 
FW (10ml.kg
-1
 distilled water + 20% fructose in drinking water) and HHS + TW groups 
(500mg.kg
-1
 HS + tap water). These differences, though statistically significant may not be of 
any biological significance. Gender differences were found in the plasma ALP concentrations 
in all the treatment groups except DW + FW (10ml.kg
-1
 distilled water + 20% fructose in 
drinking water) and LHS + TW (50mg.kg
-1
 HS + tap water). Since the male rats in all the 
treatment groups had a significantly higher body mass, the gender differences observed in 
plasma ALP levels might be from the increased osteoblastic activity associated with growth. 
However, further studies are needed to further evaluate the cause(s) of these gender 
differences following administration of a high fructose diet. 
 
3.8.7 Markers of general health 
 
Plasma concentration of calcium, phosphorus, cholesterol and activity of amylase were used 
as surrogate markers of general health. Calcium and phosphorus are involved in bone 
formation and mineralization and their metabolism is regulated by calcitonin and parathyroid 
hormone (De Paula and Rosen, 2010). Because both calcium and phosphorus are reabsorbed 
in the GIT and kidneys, an increase in their plasma concentrations correlates with an 
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increased osteoblastic activity and increased GIT or kidney absorption.  Though fructose 
feeding has been associated with an increased urinary calcium excretion (Taylor and Curhan, 
2007)  and other risks of kidney diseases, there was no significant finding in that regard in this 
study. With the exception of a gender difference (p<0.05) observed in the LHS + FW 
(50mg.kg
-1
 HS extract + 20% fructose in drinking water), there was no significant difference 
observed (p>0.05) in the plasma concentrations of both calcium and phosphorus.  
 
Amylases are enzymes which  catalyse starch, dextrins and glycogen hydrolysis into glucose  
(Janowitz and Dreiling, 1959). They are produced mainly in the salivary glands, pancreas and 
liver with contributions from fallopian tubes, striated muscles and adipose tissues (Janowitz 
and Dreiling, 1959; Simpson et al., 1991). An increase in the plasma levels of amylase is an 
important guide in the diagnosis of acute pancreatitis or of exercabation of chronic 
pancreatitis (Janowitz and Dreiling, 1959). There was no significant difference (p>0.05) in the 
plasma amylase concentration across the treatment groups suggesting that the administration 
of fructose did not have negative effects in the salivary glands and exocrine pancreata of the 
rats.  Feeding of 7 week old rats with 60% fructose (w/w)  for 8 weeks did not produce any 
adverse effects on serum amylase  (Huang et al., 2004). However, significant differences were 
found between the males and the corresponding females in the following groups: DW + TW 
(10ml.kg
-1
 distilled water + tap water), LHS + TW (50mg.kg
-1
 HS + tap water), LHS + FW 
(50mg.kg
-1
 HS + 20% fructose in drinking water) and HHS + FW (500mg.kg
-1
 HS + 20% 
fructose in drinking water).  There is a higher content  of α-amylase in the fallopian tubes  
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than in the serum of humans, cows, rabbits and sheep  but not in rats, dog, pigs, monkeys and 
cats (Janowitz and Dreiling, 1959). Still, I would have expected the plasma amylase activity 
in the females to be higher than those in the males due to the extra secretion from the 
fallopian tubes.  
Though elevated levels of serum total cholesterol have been reported in 8 week old rats 
following oral fructose administration for 8 weeks (Yadav et al., 2007), no significant 
differences were found across the treatment groups in this study . However, the female rats in 
the HHS + FW (500mg.kg
-1
 HS + 20% fructose in drinking water) had a significantly higher 
(p<0.05) plasma cholesterol concentration than their male counterparts.  Previous studies in 
humans (Seidell et al., 1991)  and mice (Bruell et al., 1962)  have reported higher serum 
cholesterol values for males compared to females.  
 
3.8.8 Conclusion 
 
In this phase of the study, male and female Sprague Dawley rats that had been administered 
with HS extracts in the neonatal period were subjected to a high fructose in their drinking 
water (20% fructose w/v). The aim was to investigate whether the initial administration of HS 
extracts would have any effect in the development of metabolic dysfunction in the rats. The 
rats did not develop features of metabolic dysfunction (hyperglycaemia, 
hypertriglycerideamia, insulin resistance, impaired glucose tolerance, hypercholesterolemia) 
after four weeks of fructose administration. The female rats that were administered with a 
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high dose HSE had a significantly greater amount of visceral fat pad compared to the male 
rats in the group. The gender differences that were observed in some of the measured 
parameters though statistically significant might not be of any biological significance.   
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CHAPTER FOUR: CONCLUSIONS AND 
RECOMMENDATIONS
4.0 Conclusion 
 
The study was done in two phases. In the first phase, the effects of HS aqueous calyx extracts 
on the growth performance, gastrointestinal tract morphometry and metabolic substrates of 
suckling rats was investigated.  This phase of the study is very important because there is a 
high chance of exposure of the neonates to this widely consumed plant. Moreover, no studies 
were found in which the HS extracts were administered to suckling rats directly. Findings 
from this phase suggest that HS when consumed in the suckling period could cause 
precocious maturation of the small intestines. Hibiscus sabdariffa aqueous calyx extracts 
however had no adverse effects on the growth performance, metabolic substrates and general 
health of the pups. 
 
In the second experiment, metabolic dysfunction was not induced despite administration of a 
20% fructose (w/v) in the drinking water of the rats for four weeks. The rats did not show the 
hypertriglyceridaemia and insulin resistance associated with fructose administration. As 
expected, in this phase, the male rats gained more weight than the female rats.  The female 
rats that had received the high dose HSE in the neonatal period had greater amount of visceral 
fat compared to the corresponding males in their groups. There was no difference in the 
response of the rats to the fructose diet between the groups that had received HS in the 
suckling period and those that did not. There were no adverse effects observed either due to 
the administration of HS or the fructose diet across all the treatment groups. The rats in the 
fructose groups drank fructose water as their only source of water though actual intake was 
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not recorded. It might be safe to conclude that the administration of the HS extracts in the 
suckling period did not have any influence on how the growing rats responded to the 20% 
fructose diet. The short term administration of 20% fructose (w/v) in the drinking water of the 
growing rats did not also induce metabolic dysfunction as suggested by literature. 
 
4.1 Limitations of the study 
 
The small amount of plasma obtained in phase one did not allow for the determination of 
hormones associated with growth such as IGF-1 and insulin. Histological samples of the small 
intestines were prepared but unfortunately were not well oriented on the slides. Histological 
findings would have revealed if there were changes in the villi height, crypt depth or the villi 
height/crypt depth ratio which would explain the increase in the masses of the small intestines 
relative to the body mass in the HS groups. The pups were also not fasted prior to termination 
in phase one because it would have required separating them from their dams and since the 
pups do not all suckle at the same time it would have been very difficult to standardise the 
duration of fasting between the different pups. Functional tests such as perfused gut loops, 
immunohistochemistry and cell cultures were not performed on the GIT to assess whether 
functional maturation also occurred in the small intestines. A higher concentration of fructose 
and a more prolonged period of its administration might have induced metabolic dysfunction 
as anticipated.  
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4.2 Recommendations  
 
For future studies, neonatal programming should be induced by manipulating the maternal 
environment through diet restriction or some other stressor events before interventions are 
instituted in the pups. A more prolonged period of fructose feeding preferably up to adulthood 
should be used to determine the effects of the programming on adult metabolic health. The 
fructose should also be administered in the diet rather than drinking water of the rats as this 
has been shown to be more potent in inducing metabolic dysfunction. 
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